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From lightening and tempest; from plague,
pestilence andfamine; from battle and murder,
andfrom sudden death, Good Lord, deliver us.
The Litany, Book ofCommon Prayer
Despite the innumerable technological and medical advances
which have occurred since the writing of the Litany, it remains clear
that sudden death is as real a problem today as it was in the 16^
century. In medical terms, 'sudden death' generally denotes death
which is nonviolent, which is unexpected, which is witnessed and
which is instantaneous or occurs within a few minutes of an abrupt
change in previous clinical state (Roberts, 1986). Since diseases of
the heart are by far the most common cause for people to die
suddenly, the word 'cardiac' is usually included, and the term 'sudden
cardiac death' applied to persons who die suddenly from ischaemic
heart disease (Eisenberg et al, 1986). An idea of the magnitude of the
problem can be gauged from epidemiological data which suggest that
sudden cardiac death may account for up to 30% of all deaths (Madsen,
1985). This is further compounded by the observation that in nearly
25% of these individuals, sudden cardiac death is the first
manifestation of underlying heart disease (Kuller, 1966). The
development of modern electrocardiographic monitoring however, has
at least allowed us better understanding of the electrophysiological
basis of the problem, and several reports have identified ventricular
fibrillation as the most common terminal mechanism (Lown and
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Graboys, 1977; Gradman et al, 1977; Hinkle et al, 1977; Nikolic et al,
1982). Furthermore, it appears that in the majority of cases
ventricular fibrillation is a primary event and not secondary to acute
myocardial infarction (Kuller et al, 1972; Baum et al, 1974; Lucchesi,
1984).
Since, once established, the only management of ventricular
fibrillation is the application of a direct current counter-shock (Lown
et al, 1962), for many years researchers and clinicians alike have
looked for treatable factors that might be identified in those at risk
of sudden cardiac death. While these people can be shown to share a
high prevalence of risk factors for ischaemic heart disease, they
cannot unfortunately be distinguished from other patients with
ischaemic heart disease (Doyle et al, 1976). However, studies of
patients after myocardial infarction have been able to identify a
number of risk factors for subsequent sudden cardiac death, and of
these, chronic ventricular ectopy appears to be of prime importance
(The Coronary Drug Project Research Group, 1973; Moss et al, 1979;
Hinkle, 1981; The Multicenter Postinfarction Research Group, 1983;
Mukharji et al, 1984; Bigger et al, 1984). As a result, there is now an
increasing awareness of the need for compounds with effective
antiarrhythmic activity in the management of such patients.
The Lord hath created medicines out of
the earth; and he that is wise will not abhor them.
With such doth he heal men, and taketh away their pains.
3
Ecclesiasticus 38,4-7.
The use of antiarrhythmic drugs may date back as far as 1749,
when Jean-Baptiste de Senac used cinchona for the treatment of
'rebellious palpitation' (Roden and Woosley, 1984). Although the
synthesis of the dextro-isomer of quinine was carried out by Pasteur
in the 19th century, it was not until 1914 that Wenchebach, the
Viennese physician, employed the drug for the management of atrial
fibrillation (Hoffman and Bigger, 1971). Since then, however, the
number of antiarrhythmic drugs has grown enormously, and over the
past 10 years a new compound has become available approximately
every six months (Vaughan Williams, 1984). When one considers that,
for every new drug presented, several more will have failed to reach
full development, one can gain an idea of the magnitude of the field of
antiarrhythmic therapy. At the same time, it becomes clear that such
research and development would not be necessary if the ideal
antiarrhythmic drug were available. Such a drug might be expected to
possess certain favourable characteristics such as low cost, simple
dosage, broad spectrum of action and freedom from side effects, but
at the end of the day the ultimate attribute will be the ability to save
lives. While many of the currently available antiarrhythmic drugs can
significantly reduce the incidence of ventricular arrhythmias, recent
reports have suggested that there is no associated improvement in
mortality (Myerburg et al, 1979; May et al, 1983; Furberg et al, 1983;
Impact Research Group, 1984). It is known that 3 adrenoceptor
blockade can reduce mortality after myocardial infarction
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(Multicenter International Study, 1975; Norwegian Multicenter Study
Group, 1981; Beta-Blocker Heart Attack Trial Research Group, 1982)
but it has been suggested that this relates more to an anti-ischaemic
than any antiarrhythmic action of the drugs (The Miami Trial Research
Group, 1985; ISIS-1 Collaborative Group, 1986). There have even been
a number of reports linking the use of antiarrhythmic drugs with a
worsening of the arrhythmia being treated (Velebit et al, 1982;
Ruskin et al, 1983; Poser et al, 1985; Torres et al, 1985).
Thus it is necessary that we continue the search for a safe,
effective antiarrhythmic compound that will improve both the quality
and the expectancy of life for the patient after myocardial infarction.
Let his heart be changedfrom
man's and let a beast's heart be
given unto him.
Daniel 4,16
Ideally the best model for the careful study of antiarrhythmic
action will be the patient with heart disease whose health is
disturbed or whose life is at risk as a result of cardiac arrhythmias.
Whilst this may be justifiable with drugs which have been shown to
possess potentially life-saving characteristics, it will be wholly
inappropriate for the initial screening investigations required of all
antiarrhythmic agents. In such cases, it becomes necessary to
substitute experimental models in the form of isolated tissue
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preparations or intact animals. As our understanding of the many
factors involved in the genesis of arrhythmias has developed, so too
have these models progressed from the relatively simple, inexpensive
methods previously employed to the highly sophisticated models
which now attempt to take into account those pathophysiological
variables (such as collateral circulation, neurohumoral influences and
underlying arterial diseases) which pertain in the human situation.
The aim of this thesis has been to gain a better understanding
of the various factors involved in the genesis of those malignant
ventricular arrhythmias which are responsible for sudden death in
man, and to study the effects (both beneficial and deleterious) of
several pharmacological compounds on ventricular arrhythmias
generated in a number of experimental animal models. Some of these
models have been employed in similar studies for many years, while
one (programmed electrical stimulation in the chronic myocardial
infarction model) represents a recent addition to the armoury of the
experimental pharmacologist. Each model is critically appraised with
regard to its applicability to the human situation, and results with
antiarrhythmic drugs are compared with previous studies, both
experimental and in man.
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Chapter 1. THE HEART
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1.1 Electrophvsioloav of the Heart
Evolutionary development has done much for the series of
tubular cardiac structures, still present in certain primative
organisms, which are now apparent as the four-chambered, four
valved, dual actioned organ of modern vertebrates (Davis, 1927).
Nevertheless the fundamental action of the heart remains that of a
pump, and as such depends upon regular, repetitive contractions
which will carry the oxygen (as blood) across its length. These
contractions are in turn controlled by a complex series of electrical
events, mediated by the movement of charged ions across the
membranes of the cardiac cells.
1.1.1. The Action Potential
Within a resting cardiac cell there is normally a negative
potential of approximately 90mv relative to the extracellular space
(the transmembrane potential). This potential is maintained by an
energy-dependent membrane pump which actively extrudes sodium
ions (Na+) from within the cell. The same pump is also responsible
for a net inward movement of potassium ions (K+), resulting in an
intracellular K+ concentration of approximately 35 times that of the
extracellular fluid, while the Na+ concentration is approximately 5
times greater in the extracellular fluid. The transmembrane
potential is thus maintained by an equilibrium where electric
gradients (for example tending to move K+ into the cells) are exactly
balanced by concentration gradients (tending to extrude K+ from
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cells) and no net ionic movement occurs. Should the transmembrane
potential be increased (i.e. moved towards zero) for any reason, a
potential exists (the threshold potential) where the mechanisms
described above temporarily break down and there is a reversal of
ionic concentrations. Such events are termed the action potential;
they are responsible for initiating myocardial contraction and are
represented on the surface electrocardiogram as the QRS complex
and T wave.
1.1.2. The Fast Response
Intracellular recordings of the same sequence of events appear
rather different, and are represented in figure 1.1. Having reached
the threshold potential, the initial rapid depolarization and
overshoot are due to a rapid increase in Na+ permeability (phase 0 of
the action potential). This fast Na+ channel (i^a" where i is the
representation for all membrane currents) may be viewed as being
guarded by a 'gate', or charge-dependent configuration of the
phospholipids within the cell membrane (Wallace, 1982). During
phase 0, the membrane potential reaches approximately +20 mv, but
never quite reaches the +50 mv predicted value since activation of
the fast Na+ channel lasts only 1-2 msec before becoming
inactivated (phase 1) (McAllister et al, 1975).
In addition to the fast sodium channel, there is a second and
much more slowly inactivated inward current which is responsible
for the plateau phase of the action potential (phase 2). This 'slow'
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current (isj) is mediated by the flux of sarcolemmal calcium (Ca+ + )
which is essential for contraction. Originally thought to be just one
channel, recent work has shown that isj probably involves a number
of separate mechanisms (Hart, 1985). Repolarization of the action
potential (phase 3) is brought about by an outward K+ movement (i^)
which activates slowly on depolarisation but deactivates rapidly
once repolarisation has taken place (Hart, 1985). As the plateau
phase of the action potential is responsible for the ST segment of
the ECG, so repolarization corresponds with the T wave.
1.1.3. Refractoriness
During the sequence of events described, the myocardial cell
will be unable to conduct another impulse; this so-called refractory
period can be divided into an absolute refractory period,
corresponding to the period from the time threshold is reached until
the point where repolarization has returned the membrane potential
to at least -50 mv (Weidmann, 1955) and a relative refractory
period, lasting from this point to the return of the normal resting
membrane potential. During the absolute refractory period no
stimulus, no matter how strong, will produce an action potential,
but during the relative refractory period stronger than normal
stimuli can cause excitation. The effective refractory period (ERP)
is the main determinant of the number of propagated impulses the
heart can generate (Singh and Nadamanee, 1982); it is often used as
an experimental parameter for measuring the shortest interval
1 0
between 2 stimuli capable of conducting respective beats (Simson et
al, 1979) (figure 2.1). The functional refractory period (FRP) is an
equivalent of the ERP but also inversely related to conductivity.
(Ferrier and Dresel, 1974). Usually used as an index of
refractoriness at the AV node, the FRP may, however, be employed
for any area of myocardium under study.
1.1.4. The Slow Response
While the above description (the 'fast' response) is
characteristic of normal atrial and ventricular muscle cells and of
Purkinje fibres, the corresponding action potentials for the
pacemaker cells of the sinus and atrioventricular nodes appear
altogether different (figure 1.2). In these fibres, resting membrane
potential is -40 to -70 mv (cf. -80 to -90 mv in 'fast' response
fibres), upstroke velocity is very slow, resulting in the term 'slow'
response fibres. The most striking difference between the two
action potential configurations is the spontaneous diastolic
depolarisation (phase 4) seen in the pacemaker cells. The ionic basis
of this appears to lie in a decrease in the outward K+ current (i^-
but known as ix^ in pacemaker tissue) allowing an inward current of
Na+ (if) to initiate depolarisation (Hart, 1985). Furthermore, since
slow-response action potentials are not altered by tetrodotoxin
(which blocks ij\ja) but are abolished by manganese or verapamil
(which antagonise isj), it appears that they are mediated solely by
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slow (Ca++) currents (Wit and Cranefield, 1974).
Under physiological conditions, slow-response action
potentials play an important role in the propagation of impulses
within nodal tissues; this is particularly so at the atrioventricular
node, where they ensure optimal cardiac performance by delaying
ventricular systole until after atrial contraction (Zipes and Fischer,
1974). Yet the slow response is not recorded from these types of
fibre only, as disease processes may alter the ionic mechanisms
underlying action potential generation in non-conducting tissues
such that they also show slow response activity. Thus diseases may
convert fast atrial and ventricular fibres into slow-response fibres
(Wit et al, 1974 (a)). The nature of the slow response (viz. low rate
of depolarization and low amplitude of action potential) results in
extremely slow conduction, and has been held responsible for the
reentrant arrhythmias responsible for sudden death in man
(Sperelakis, 1984).
1.1.5. The Effects of Ischaemia
Mention has already been made of the slowing of action
potential propagation which may occur in ischaemic conditions
(1.1.4.). Yet this is only one of a number of electrophysiological
derangements, the understanding of which is gaining increasing
importance as clinicians and electrophysiologists alike attempt to
define the conditions contributing to life-threating arrhythmias in
man. It is known, for example, that acute ischaemia causes
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depolarisation of the resting membrane, a decrease in the rate of
rise and overshoot of the action potential and a decrease in action
potential duration (Prinzmetal et al, 1961; Russell et al, 1979).
Conduction initially speeds, before slowing to the point of
fractionation or block (Boineau and Cox, 1973; Williams et al, 1974)
and similar changes are apparent with refractory periods (Russell
and Oliver, 1978). These abnormalities result from the metabolic,
ionic and neurohumeral changes which result from the abrupt
interruption of coronary blood flow (Gettes, 1986); while many of
these changes have yet to be identified, an idea of the
arrhythmogenic nature of ischaemia may be gained by looking at the
electrophysiological effects of the individual components of
ischaemia.
The dominant effect of hypoxia is to shorten the action
potential duration in all cardiac cell types (Morena et al, 1980). This
is thought to be mediated by increased potassium efflux from the
cell (Vleugels and Carmeliet, 1976). Since shortening of action
potential duration is likely to be paralleled by similar changes in
refractoriness, this represents an inherently arrhythmogenic
process, since shortening of refractionness may allow early
depolarization of fibres in an adjacent reentrant pathway (1.2.3.).
An increase in extracellular potassium results in a number of
electrophysiological derangements, including depolarization of the
membrane potential and reduction in the rate of rise of the action
potential upstroke (phase 0), lowering the action potential
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amplitude and plateau potential (phase 2), accelerating rapid
repolarization (phase 3), and decreasing the spontaneous diastolic
depolarization (phase 4) (Weidman, 1956; Hoffman and Cranefield,
1960). The initial effect of this is to render the myocardium more
excitable; although further increases in potassium decrease
excitability, conduction then becomes impaired, so maintaining the
arrhythmogenic environment (Gettes, 1986).
The major electrophysiological effect of acidosis is a slowing
of conduction (Gettes, 1986). This may be associated with a
decrease in the rate of rise of the action potential, but it is not
thought to be a cause-and-effect phenomenon; rather it is believed
that the slowing of conduction relates to alterations in cellular
uncoupling (Gettes, 1986). Acidosis has also been shown to decrease
influx and efflux of calcium, and this has been reported as a
mechanism for the induction of slow response activity (Davis et al,
1976).
Under physiological conditions, the predominant adrenergic
receptor in the heart is of the 6 type, where it mediates increased
spontaneous depolarizations in both fast- and slow-response fibres,
enhances speed of conduction, shortens refractory periods and
increases the force of contraction (Sharma and Corr, 1983). These
effects have been attributed to catecholamine-induced increases in
cyclic AMP (Tsien, 1972). Under ischaemic conditions, there are
known to be increases in both circulating (Richardson, 1963) and
neurogenic (Corr and Gillis, 1978) catecholamines, and enhanced
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B-stimulation may be arrhythmogenic by increasing oxygen demand,
contributing to hypokalaemia (Struthers et al, 1981) and favouring
the emergence of slow-response activity (Sharma and Corr, 1983). It
has also been suggested that enhanced a adrenergic responsiveness
may be a feature of ischaemia (Sheridan et al, 1980) and further
contribute to arrhythmia production by its effects on intracellular
calcium fluxes (Corr and Sharma, 1984). These points will be
discussed in more detail at a later stage (chapters 5,6,11.).
1.2. The Arrhythmia Concept
The term arrhythmia* can be applied to any condition which
affects the normal sequence of an impulse arising in the sinoatrial
node and resulting in a normal atrial activation coupled at a
physiological interval to a normal ventricular contraction. By
definition therefore, we should include conditions of
atrioventricular block, bundle branch and fascicular blocks and
bradyarrhythmias as well as the various tachyarrhythmias which
more commonly spring to mind. However, having described the
electrophysiological bases for arrhythmia genesis, the discussion
*Strictly speaking the term arrhythmia applies (as do all conditions with the
prefix a-, or an-) to a condition where no_ rhythm exists, i.e. asystole.
Semantics would therefore dictate we use the word dysrhythmia.
Unfortunately, however, old habits die hard and I use the former term with
these shortcomings accepted.
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will therefore be confined to the ventricular tachycardias
(premature ventricular contractions, paroxysmal and sustained
ventricular tachycardia, and ventricular fibrillation) which are the
cause of such great concern in our society today.
It has become customary to consider the mechanism thought to
be responsible for the genesis and perpetuation of cardiac
arrhythmia under three headings, viz. disorders of impulse
formation, disorders of impulse conduction, and a combination of
both of these mechanisms
1.2.1. Automaticitv
Reference has already been made to the ability of cells within
the conducting system of the heart to undergo spontaneous
depolarization. This property is termed automaticity, and may be
seen also in certain specialized atrial fibres, in fibres around the
coronary sinus and mitral and tricuspid valve leaflets, and in the
His-Purkinje system (Hoffman and Cranefield, 1960). Automaticity
is more common is slow-response fibres, where it is thought to
depend on a balance between ixi and if (Hart, 1985) but it is likely
that a number of ionic mechanisms may initiate spontaneous
depolarisation, since:
(a) alterations in ionic environment may affect the automaticity of
different fibres in different ways.
(b) drugs may abolish automaticity in some fibres without affecting
others.
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(c) automatic fibres respond in different ways to electrical
stimulation (Wit et al, 1974 (a)).
Fast fibres (particularly those of the specialized conducting
system) are also capable of automaticity and it appears that the
resultant action potentials may be of the slow or fast varieties (Wit
et al, 1974 (a)).
The pacemaker site of the heart is that site (usually the SA
node) with the great degree of automaticity. However, if this is
suppressed, or if conduction of the impulse is impaired (for example
by vagal stimulation), then the pacemaker function may be taken
over by 'lower' sites within the conducting system. Similarly,
enhancement of automaticity (for example by disease processes)
may result in a shift of the site of the pacemaker to an ectopic
focus (Vassalle, 1971), where initiation of an impulse may spread to
involve all of the heart, resulting in atrial or ventricular
tachyarrhythmias. An example of this can be seen in the increased
spontaneous diastolic depolarization of Purkinje fibres surviving
experimental coronary artery occlusion in dogs (Friedman et al,
1973).
If an automatic focus is interrupted by electrical stimulation,
providing the rate of stimulation exceeds the automaticity of the
arrhythmic focus, the stimuli will 'capture' the heart beat and
override the arrhythmia ('override suppression'). Cessation of
stimulation will then be followed by a period of quiescence before
the ectopic rhythm gradually re-establishes itself (Vassalle, 1970).
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Such a response to stimulation is generally taken as implying the
automatic nature of an arrhythmia.
1.2.2. Triggering
One feature which distinguishes automaticity from disorders
of impulse propagation is the ability to arise spontaneously and
independent of any initiating impulse. Under certain circumstances,
however, automatic foci may require such activation, and will
remain quiescent in the absence of such a 'trigger' (Hoffman and
Rosen, 1981). These are triggered arrhythmias, and have been further
categorised into those initiated by early afterdepolarizations and
late afterdepolarizations (Cranefield, 1977).
Arrhythmias due to early afterdepolarizations occur when the
fibre fails to repolarize completely after generating an action
potential. As the membrane potential lingers at intermediate values,
oscillatory depolarizations can arise, attain threshold and initiate
further responses (Hoffman and Rosen, 1981). Delayed
afterdepolarizations occur after phase 3 of the action potential has
restored the negative membrane potential, but usually to a value
somewhat less (negative) than normal (Hoffman and Rosen, 1981).
Since many triggered arrhythmias can be reduced or abolished
by agents which antagonize the slow channel (Rosen et al, 1974), it
might appear that such arrhythmias result from activation of slow
response fibres; However, afterdepolarizations have also been
identified in fast response units (Cranefield, 1980).
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1.2.3. Reentry
Under physiological conditions the cardiac impulse, having
sequentially activated the atria and ventricles, will terminate
spontaneously since it will be surrounded by recently excited and
thus refractory tissue. The concept of reentry (first described by
Mines in 1913) implies that the impulse persists within the
myocardium to re-excite areas no longer refractory and thus set up a
continuous circuit of impulse generation, the so-called 'circus'
movement. A functional 'loop' of myocardium is not a difficult
concept, since many cardiac fibres can conduct in 2 directions and
cross-connections between fibres have been demonstrated
(Gallagher, 1982). However, a reentrant circuit does depend on there
being an area of unidirectional block within the myocardium, and
also that the speed of the impulse is sufficiently slow to allow
recovery of the proximal fibres before re-excitation by the
wave-front (Wit et al, 1974 (b)).
In order for an impulse to travel retrogradely along a reentrant
pathway requires the presence of an area which is unable to conduct
the uniform antegrade depolarization of an approaching impulse; if
the proximal tissues have by this stage recovered from
refractionness, the conditions for reentry are established (figure
1.3).
Considering the rapid velocity of conduction of normal atrial
and ventricular cells, it was previously thought that reentry would
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be impossible outwith the AV node, as the loop would have to be
unrealistically long to allow recovery of the proximal tissues (Wit
et al, 1974 (b)). With the demonstration that disease states could
alter the conduction velocity of fast fibres, however (Wit et al,
1974 (a)), came the realization that small reentrant pathways could
be responsible for ventricular arrhythmias both in animals
(El-Sherif et al, 1977 (a)) and man (Josephson et al, 1978 (a)).
While Ca+ + -dependent, slow response fibres are almost
certainly involved in the genesis of AV nodal tachycardias (Wit et al,
1974 (c)), the situation is less clear with ventricular arrhythmias.
Mention has already been made regarding the conversion of fast to
slow fibres in certain disease states, but whether these are true
Ca + + -dependent slow fibres, or merely depressed fast fibres
remains unclear (Sperelakis, 1984). Ca++ channel antagonists have
been shown to possess ventricular antiarrhythmic activity in
experimental models, but not in man (Opie et al, 1984).
Reentry has been further divided into 'ordered reentry' and
'random reentry' (Hoffman and Rosen, 1981). In the former, the
arrhythmia occurs over a circumscribed path with a finite
anatomical reality, such as AV nodal reentry. Fibrillation (whether
atrial or ventricular), would be an example of random reentry, with a
number of randomly changing pathways, varying with time and
impulse propagation. The main advantage of this system appears to
be the differentiation of the 'benign' (largely supraventricular)
reentrant pathways from the potentially life-threatening
20
ventricular arrhythmias in man which have also been shown to
depend on reentrant mechanisms (El-Sherif et al, 1977 (a);
Josephson et al, 1978 (a), (b)).
Predictable and reproducible initiation and termination of a
tachyarrhythmia by appropriately timed electrical stimulation has
been considered the sine qua non of a reentrant mechanism (Wellens,
1977; Josephson et al, 1978 (b)). While this is generally the case,
and contrasts with the overdrive suppression of automatic
arrhythmias, it should be remembered that an appropriately timed
stimulus may act as a trigger for the initiation of early or late
afterdepolarizations (Wit et al, 1974 (a)) (1.2.2).
1.2.4. Parasystole
Having considered disorders of impulse formation
(automaticity and triggering) and disorders of conduction (reentry),
it is appropriate to consider also those arrhythmias arising from a
combination of both mechanisms
Parasystole is an independent, ectopic rhythm which functions
autonymously with the primary heart rhythm. Its pacemaker is
protected from excitation from outside impulses by unidirectional
block, helping it effectively to function as a fixed rate artificial
pacemaker (Gallagher, 1982). Parasystole is more frequently
encountered in chronically diseased hearts (Chung, 1968) but
because the inherent rate of the parasystolic focus is usually slow
(20-60 beats per minute), the phenomenon in itself is unlikely to be
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life-threatening (Gallagher, 1982).
Arrhythmias may be a feature of any disease process directly
affecting the heart. Similarly they may be the cardiac reflection of
generalized metabolic, endocrine or infective processes. This
accepted, however, there is no doubt that the commonest
pathological process responsible for life-threatening arrhythmias in
man is atheromatous narrowing of the coronary arteries-ischaemic
heart disease.
1.3. Ischaemic Heart Disease
Relatively uncommon under the age of 40, the incidence of
ischaemic heart disease (IHD) increases steadily with age. Under the
age of 45, the incidence in men is more than 10 times that in
women, but this difference becomes less apparent with increasing
age so that in the over-65 age group the respective incidences are
approximately equal (Julian, 1979).
While myocardial ischaemia may result from a number of
processes, the term IHD generally applies to ischaemia of
atheromatous origin. This is still not fully understood, but is
thought to involve the deposition of fatty substances, especially
cholesterol, in the arterial intima. Various risk factors have been
identified for the process, and include hypertension,
hyperlipidaemia, diabetes, cigarette smoking, family history, the
degree of physical activity and possibly mental stress (Julian,
1979). Although this appears to be a process which starts early in
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life (Zelis and Wenger, 1982) IHD nevertheless remains a clinical
diagnosis, usually presenting as angina pectoris, acute myocardial
infarction or sudden cardiac death.
1.3.1. Angina Pectoris and Acute Myocardial Infarction
Angina pectoris is a syndrome resulting from an imbalance
between the oxygen demand of, and the oxygen supply to, the
myocardium (Julian, 1979). It classically presents as a retrosternal
pain, usually described as a 'tightness' or 'heaviness' which often
radiates to the neck, jaw and arms. The pain is usually provoked by
exercise, particularly after a heavy meal or in cold weather.
Emotional upset may also act as a trigger, while some patients only
experience attacks at night or when lying flat (angina decubitus).
Cessation of exercise will usually terminate the attack, which
characteristically lasts from 1 to 3 minutes. Pain lasting more than
3 minutes should raise the suspicion of myocardial infarction (see
below).
Most patients with angina pectoris manage to live a fairly
normal life, although they may have to modify their daily routine to
avoid precipitating attacks. The danger to the patient is not of the
angina attack itself, but of the increased risk of going on to develop
an acute myocardial infarction.
The essential pathological feature of acute myocardial
infarction (a 'heart attack') is myocardial necrosis, usually the
consequence of total occlusion of a coronary artery (Julian, 1979). It
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often presents with features indistinguishable from a severe angina
attack, but usually unrelated to exercise and tending to last more
than 30 minutes. Treatment with anti-anginal vasodilators will be
ineffective. The diagnosis can subsequently be confirmed by
demonstrating the characteristic ECG changes (ST elevation, T wave
inversion and development of Q waves) and identifying circulating
enzyme markers (especially myocardial-specific creatine
phosphokinase: CK-MB) from the necrotic area of myocardium. The
complications of acute myocardial infarction can generally be
divided into those occurring within the first 2-3 days (the early
complications) and those which threaten the patient after this
period (late complications).
Arrhythmias are by far the most important early complication
of acute myocardial infarction, occuring in over 90% of patients
within 4 hours (Pantridge et al, 1975). The indications for treating
arrhythmias are twofold: firstly, to correct an arrhythmia (such as a
marked bradycardia, heart block or tachyarrhythmia) which impairs
cardiac output. These are particularly common in the acute phase,
where they are often associated with autonomic disturbances
(Pantridge et al, 1975). Secondly, there is the question of treating
the so-called 'warning' arrhythmias that are thought to be
harbingers of ventricular fibrillation. In the past it was considered
that frequent, multifocal or the so-called 'R-on-T' ventricular
ectopics were associated with a high risk of ventricular fibrillation
and required immediate antiarrhythmic therapy (Mounsey, 1967;
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Thomas et al, 1968). However, subsequent findings have suggested
that this may be incorrect; ventricular arrhythmias may occur
without preceding events, and 'warning arrhythmias' are as common
in those who do not proceed to ventricular fibrillation as in those
who do (Julian, 1986). Nevertheless, the occurrence of an early
ventricular ectopic of the 'R on T' variety is often the trigger for
ventricular fibrillation (figure 1.4).
The late complications of myocardial infarction include
thromboembolic phenomena, the risk of reinfarction and/or sudden
death, heart failure, ventricular aneurysm and a number of
psychological and social difficulties the patient may have to face.
1.3.2. Sudden Cardiac Death
First described as a distinct entity almost a century ago
(MacWilliam, 1889), the incidence of sudden cardiac death has been
estimated at 2-3% per year in patients with ischaemic heart
disease. The syndrome has been defined variously as death occurring
within 30 seconds of the onset of acute symptoms ('instantaneous
death') (Friedman et al, 1973) to that occurring within 2 hours
(Helmers et al, 1976), 2 days (Paul and Schatz, 1971) or 6 days
(Meade et al, 1968). A more acceptable definition now appears to be
death which occurs within one hour of the onset of acute symptoms
(Gordon and Kannel, 1971; Myerburg, 1978; Goldstein, 1982),
although it should be remembered that symptoms may be entirely
absent in some cases.
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Although, sudden death may occur in the setting of acute
myocardial infarction, the majority of cases are not associated with
myocardial necrosis (Kulier, 1972; Baum et al, 1974; Lucchesi,
1984). In most cases, death is the result of a primary electrical
event within an unstable myocardial environment (Podrid, 1985) and
usually occurs outwith the hospital environment (Spiekerman et al,
1962). Several studies with ambulatory electrocardiographic
monitoring have identified ventricular fibrillation as the most
common terminal mechanism (Gradman et al, 1977; Hinkle et al,
1977; Nikolic et al, 1982), often preceded by a variable period of
unimorphic ventricular tachycardia (Panidis and Morganroth, 1983;
Pratt et al, 1983; Kempf and Josephson,1984; Milner et al, 1985).
Although an unstable electric milieu is a necessary prerequisite for
ventricular fibrillation, it is not sufficient per se to cause sudden
death. Recent evidence suggests that transient, acute ischaemia
(whether produced by platelet aggregation, coronary artery spasm or
autonomic activity) may well be the important triggering event
which predisposes for the development of lethal arrhythmias, both
in experimental models and in post-infarction patients (Gradman et
al, 1977; Theroux et al, 1979; Podrid, 1985; Lynch and Lucchesi,
1987).
The fact that sudden cardiac death may strike suddenly and
unexpectedly in the months following myocardial infarction has
prompted much research into defining those post-infarction risk
factors which might be modified in the hope of improving prognosis.
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In general, two groups of risk factors have been identified: those
indicating left ventricular dysfunction and those associated with
arrhythmias.
A number of investigators have demonstrated an independent
association between left ventricular failure and the risk of sudden
death in post-infarction patients (the Multicenter Postinfarction
Research Group, 1983; Bigger et al, 1984; Mukharji et al, 1984).
While these studies have generally based their data on radionuclide
ejection fractions, in general simple clinical observations appear to
offer as valuable prognostic information as do more expensive or
invasive ones (Julian, 1981).
It has been shown that ventricular arrhythmias noted during
the early phase of acute myocardial infarction appear to have little
influence upon the subsequent course (Vismara et al, 1975). The
continued presence of such ectopy, however, has been identified as a
risk for subsequent sudden cardiac death in numerous studies
(Coronary Drug Project Research Group, 1973; Hinkle et al, 1977;
Moss et al, 1979; Multicenter Postinfarction Research Group, 1983;
Bigger et al, 1984; Mukharji et al, 1984). It is for this reason that
the management of chronic ventricular ectopy has posed a serious




























Phases of the action potential of a cardiac muscle fibre



























Conducting system of the heart with typical transmembrane
action potentials for the SA node, AV node, and atrial and
ventricular muscle.
(Reproduced from: Ganong WF, ed. Review of medical physiology.
California: Lange medical publications,1985.)
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Figure 3.
Mechanism of reentry. The hypothetical circuit shows a proximal wavefront dividing into
2 divergent pathways (a,p), and uniting to form a distal common pathway.
A, Normal conduction in a and p.
B, Unidirectional block in p.
C, Impulse travels retrogradely along p.
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Figure 4.
Examples of arrhythmias:
A, Ventricular ectopic occurring late-cycle.
B, Early-cycle ('R on T') ventricular ectopic.
C, Salvo of 3 ventricular ectopics.
D, Short run of slow ventricular tachycardia.
E, ventricular fibrillation precipitated by R on T ectopic.
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Chapter 2. MANAGEMENT OF CARDIAC ARRHYTHMIAS
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2.1 Non-Drua Treatment
Whilst this thesis is largely concerned with the drug
management of life-threatening ventricular arrhythmias, it is
important to realize that other, non-pharmacological, methods exist
for the same purpose. Accordingly, it is appropriate to discuss these
briefly.
2.1.1 Implantable Defibrillators.
The reality of reversing ventricular fibrillation goes back to
1899, when Prevost and Battelli observed that a strong electric
current could terminate experimental ventricular fibrillation
(Prevost and Battelli, 1899). The first successful resuscitation of a
patient appears to have been by Beck (1947), but the need for
thoracotomy and direct application of the electrodes had obvious
clinical limitations. Experimental closed chest defibrillation was
first described in 1936 (Ferris et al, 1936) before being
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successfully demonstrated in man two decades later (Zoll et al,
1956). Lown et al (1962) demonstrated that direct current (DC)
shocks were preferable to alternating current (AC) in terms of
successful resuscitation, damage to the heart and paradoxical
induction of arrhythmias. Such advances have led to the development
of the mobile coronary care units, where resuscitating equipment
can be brought to the patient at the first signs of myocardial
infarction (Pantridge et al, 1975).
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The introduction of an automatic implantable defibrillator in
the late 1970's provided permanently available defibrillating
capabilities to the patient at high risk of sudden death, without
requiring specialized personnel or additional equipment (Mirowski et
al, 1981). The device is programmed continuously to monitor the
cardiac rhythm, to recognise ventricular tachycardia and ventricular
fibrillation, and to deliver corrective defibrillator charges when
indicated (Mirowski et al, 1981). However, as the authors
themselves recognise, "many problems remain to be solved and the
ultimate value of this new therapeutic modality has yet to be
determined".
2.1.2 Automatic Pacemakers
The first report of cardiac pacing for the management of
ventricular tachyarrhythmias appears to have been in 1964 (Sowton
et al, 1964). Since then, techniques have been modified and improved
to the point where pacing now plays a major role in the diagnosis
and management of arrhythmias (Griffin et al, 1981). McCallister et
al (1966) described an implantable pacemaker capable of continuous
rapid overdrive suppression of ventricular arrhythmias, before it
was discovered that the same end could be achieved by bursts of
rapid stimuli (Bennett and Pentecost, 1971). In 1978 Peters and
co-workers reported on an externally controlled, radiofrequency
pacemaker (Peters et al, 1978), and more recently we have seen the
development of a multiprogrammable, automatically activating
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ventricular burst pacemaker (Griffin et al, 1981). The principal
hazards of these newer devices is acceleration of the tachycardia or
induction of ventricular fibrillation, and they should therefore be
instituted only after thorough electrophysiological assessment
(Griffin et al, 1981).
2.1.3 Surgical Resection
It has been known for some time that patients with ventricular
aneurysms exhibit a high frequency of ventricular arrhythmias (Sami
et al, 1978). Following the reported benefit of surgical
aneurysmectomy (Couch, 1959) this became a standard procedure,
although long-term results of 'blind' aneurysmectomy have been
equivocal (Sami et al, 1978; Gallagher, 1978). Recent interest has
been renewed, however, with the technique of combining surgery
with per-operative electrophysiological studies: using composite
electrodes it is now possible during surgery to record electrical
activity from various epicardial sites both in sinus rhythm and
(induced) ventricular tachycardia ; from the resulting epicardial
'map' the cardiologist can then identify the point of origin of the
arrhythmias and guide ventriculotomy accordingly (Fontaine et al,
1979; Horowitz et al, 1980; Mason et al, 1982).
2.2 Drug Treatment
2.2.1 Classification of Antiarrhythmic Drugs
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From the time it was first recognised that drugs had an
important role in the management of patients with heart disease, it
was realised that the agents employed did not form an homogeneous
group. They differed greatly in chemical structure, in
pharmacokinetic characteristics and in their electrophysiological
effects. This was particularly so with respect to the intracellular^
recorded action potentials from different parts of the heart . For
this reason it became desirable to identify those
electrophysiological features which could be correlated with a
particular therapeutic response; such an approach has formed the
basis for the categorisation of actions of antiarrhythmic drugs
(Vaughan Williams, 1970; Hoffman and Bigger, 1971; Singh and
Vaughan Williams, 1972 (a); Vaughan Williams, 1975; Gettes, 1979;
Vaughan Williams, 1984).
The classification which appears to have gained the greatest
acceptance is that originally described by Vaughan Williams (1970).
This is based on the effects of any antiarrhythmic compound being
related to:
(i) depression of the fast response
(ii) inhibition of sympathethic activity to the heart
(iii) homogeneous prologation of the action potential duration
(iv) depression of the slow response.
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The original classification of antiarrhythmic drugs
(Vaughan Williams, 1975)
2.2.2 Class 1
These compounds (table 2.1) all share the property of being
able to reduce the maximum rate of depolarization (MRD) in cardiac
muscle. This they achieve by reducing the fast sodium current, which
can be measured as a change in phase 0 of the action potential.
Additional features of these drugs include an increase in the
threshold of excitability, a depression in conduction velocity and a
prolongation of the effective refractory period (ERP) (Singh and
Nadamanee, 1982). Of these, prolongation of the ERP may be a
particularly important process in explaining the actions of these
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drugs in terminating reentrant pathways; this is most likely due to
attachment of the drugs to sodium channels in their inactivated (ie.
post-depolarization) state and prolonging that state for a variable
period (Vaughan Williams, 1984).
More recently it has been suggested that class 1 should be
further divided into three sub-groups (Harrison, 1983; Vaughan
Williams, 1984) (table 2.2). This relates primarily to the effects on
action potential duration (APD) by the drugs in the various groups.
Thus class 1a drugs such as quinidine, procainamide and
disopyramide prolong APD, class 1b drugs such as lignocaine,
mexiletine and tocainide shorten APD, while class 1c drugs
(encaidine, flecainide, lorcainide) have little effect. The
pharmacological basis for this sub-grouping may well relate to the
speed of dissociation of the drugs from the inactivated sodium
channels (Vaughan Williams, 1984). Since shortening of APD is an
inherently arrhythmogenic process (chapter 1.1.5), it is important to
realize that class 1b drugs remain antiarrhythmic by nature of a
relative increase in the ratio of effective refractory period to
action potential duration (ERP:ADP ratio) (Harrison,1983) (figure
2.1).
The ability of all class I drugs to slow the maximum rate of
depolarization (MRD) is often referred to as 'membrane stabilizing
activity'. Similarly, since at 10 to 100 their antiarrhythmic























Subdivisions of class I antiarrhythmic drugs
(adapted from: Vaughan Williams, 1984)
term 'local anaesthetic action' is frequently substituted to describe
the drugs' action on the heart. As quinidine was the prototype of the
group, the expression 'quinidine-like' is a further alternative.
2.2.3. Class 2
Class 2 antiarrhythmic drugs block sympathethic drive to the
heart, and it should be noted that in Vaughan Williams' original
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classification no restriction were placed as to where (anatomically
or pharmacologically) this antagonism should occur (Vaughan
Williams, 1975). Nevertheless, since sympathethic drive is mediated
primarily by 6 receptors, class 2 activity has largely become
synonymous with B-adrenergic blockade (Morganroth, 1985).
The B-adrenergic antagonists (B blockers) may be variously
classified according to their respective hydro-or lipophilicity, their
selectivity for the B-| receptor subtype or their intrinsic
sympathomimetic (partial agonist) activity, but the common action
on the heart appears to be depression of phase 4 depolarization
(Singh and Nadamanee, 1982). For this reason the drugs are
particularly useful in the management of arrhythmias dependent
upon impulse transmission through the AV node (Singh and
Nadamanee, 1982). Ventricular arrhythmias resulting from mitral
valve prolapse, hypertrophic cardiomyopathy or in the setting of
myocardial sensitization by anaesthetic agents may also respond to
B-adrenergic antagonists, but generally these drugs are only weakly
antiarrhythmic in ventricular tachycardias (Morganroth, 1985). One
exception may be where such arrhythmias are dependent upon
enhanced sympathetic drive (chapter 1.1.5).
2.2.4 Class 3
One interesting aspect of the Vaughan Williams classification
is that the third class of antiarrhythmic action existed as a











Acebutolol 0.3 + + + 0.68
Alprenolol 0.3 - + + 3.1
Atenolol 1 + - - <0.02
Metoprolol 1 + - + 0.2
Nadolol 1 - - - 0.02
Oxprenolol 0.5-1 - + + 0.7
Pindolol 6 - ++ + 0.2
Practolol 0.3 + + - <0.02
Propanolol 1 - - + 4.3
Sotalol 0.3 - - - <0.02
Timolol 6 _ _ _ 0.3
Table 2.3
Properties of the currently available (3-adrenergic antagonists
required characteristics of the group. This was based on the
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observation that in hyperthyroidism (where shortening of action
potential duration is characteristic) arrhythmias are common,
whereas in myxoedema (where action potentials are uniformly
prolonged) arrhythmias are rare (Vaughan Williams, 1970). When the
anti-anginal agent amiodarone was found uniformly to prolong action
potential duration in association with significant antiarrhythmic
activity for which no other explanation was apparent (Singh and
Vaughan Williams, 1970), it became the prototype of the class 3
agents. It should be noted that the mechanism whereby amiodarone
lengthens action potential duration and effective refractory period
differs fundamently from the class 1a drugs. The latter produce a
time-dependent increase in refractoriness by altering sodium
conductance during depolarization whereas the class 3 drugs exert
their effects via a voltage-dependent change in refractoriness by
slowing repolarization (Singh and Nadamanee, 1982).
It is also important here to distinguish between homogenous
prolongation of the action potential as occurs with class 3 drugs and
is antiarrhythmic, and the heterogenous prolongation seen in the
so-called 'long QT syndromes' (whether hereditary or acquired)
which lead to spatial variation in refractoriness and subsequent
arrhythmogenicity (Ward, 1964; Khan et al, 1981)(chapter 2.4).
2.2.5 Class 4
That there existed a fourth class of antiarrhythmic action
was first suggested by Singh and Vaughan Williams (1972(a)) when
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studies with the drug verapamil revealed antiarrhythmic effects
which could not be attributed to any of the then three classes of
action. Since then the calcium channel blocking agents (or calcium
antagonists, as they are commonly known) have gained increasing
importance not only as antiarrhythmic agents, but also in myocardial
ischaemia, systemic and pulmonary hypertension, and hypertrophic
cardiomyopathy (Braunwald, 1982).
Since the nodal pathways of the heart are normally depolarized
by slow inward currents (chapter 1.1.4), verapamil (the prototype of
the class with the greatest antiarrhythmic action) has now became
the drug of choice in the management of paroxysmal
supraventricular tachycardia (Krikler and Spurrell, 1974; Lazzara
and Scherlag, 1980). However calcium antagonists in general have
been disappointing in the treatment of ventricular arrhythmia
(Lazzara and Scherlag, 1980; Vaughan Williams, 1984). After what
has been said about the possible role of slow-response fibres in
ischaemic arrhythmias (chapter 1.1.4), this might appear surprising;
however, attenuation of ischaemic arrhythmias by calcium
antagonists has been described in a number of experimental models
(El-Sherif and Lazzara, 1979; Brooks et al, 1980; Curtis et al, 1984)
and has been explained on the basis of improved cell-to-cell
conduction consequent upon falls in intracellular calcium (Vaughan
Williams, 1984).
2.2.6 Comments on the Vauahan Williams Classification
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As Vaughan Williams himself has written: "the classification
is not so much categorization of drugs, in accordance with chemical
structures or physical properties, but describes four ways in which
abnormal cardiac rhythms can be corrected or prevented" (Vaughan
Williams, 1984). It follows therefore that one should not assume
that a drug's action is necessarily limited to the class in which it is
to be found. Class 1a drugs such as disopyramide and quinidine
possess marked anticholinergic effects which are not included in the
classification despite profound cardiac effects (Goldstein et al,
1973). The same drugs, by prolonging action potential duration, also
possess inherent class 3 activity, a feature also shared by the
B-adrenergic antagonist sotalol (Strauss et al, 1970). It is
interesting that, while acute prolongation of action potential
duration is not seen with other B-adrenoceptor antagonists, a
similar effect may be observed after long-term B-blockade in man
(Edvardsson and Olsson, 1981), and this has been suggested as the
mechanism by which these drugs confer protection from reinfarction
and sudden death (Raine and Vaughan Williams, 1976) (chapter 2.4).
So the list could continue with the membrane-stabilizing
activity seen in many class 2 drugs (Shanks, 1976) (table 2.3), and
the class 4 drug perhexiline (Singh and Nadamanee, 1982). Similarly,
electrophysiological studies with amiodarone have revealed features
which could include the drug in each of the four antiarrhythmic
classes (Bexton and Camm, 1982; Gloor et al, 1983; Mason et al,
1984). More recently, the advent of the specific bradycardic agents
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has provided a class of drugs which are thought to act primarily by
anion antagonism and thus require separate (class 5) consideration
(Millar and Vaughan Williams, 1981).
2.3 Drugs and Sudden Cardiac Death
Although there is a clear relationship between the presence of
chronic ventricular ectopic beats and the risk of sudden death, there
is little evidence that suppression of ectopy with conventional
antiarrhythmic agents has a favourable outcome. Indeed, a number of
studies with currently available agents have failed to show any
reduction in mortality in controlled trials. May et al (1983)
reviewed the results of 14 clinical trials involving 3625 patients
with myocardial infarction who were treated with one of four class
1 antiarrhythmic drugs (quinidine, lignocaine, procainamide or
disopyramide). Each agent was reported to suppress ventricular
arrhythmias during the acute phase of myocardial infarction but
none of the trials demonstrated any associated reduction in
mortality. Similar results were published by Furberg (1983) in a
review of 6 clinical trials with four similar class 1 agents
(mexiletine, tocainide, phenytoin, aprindine) and the IMPACT
Research Group (1984) which specifically studied the use of a
sustained-release preparation of mexiletine. Conversely, however, a
number of trials have provided good evidence that the use of
B-adrenoceptor antagonists in the post-infarction period is
associated with a reduction in both reinfarction and sudden death
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(Multicenter International Study, 1975; Norwegian Multicenter Study
Group, 1981; Beta-Blocker Heart Attack Trial Research Group, 1982;
Yusuf et al, 1985; The Miami Trial Research Group, 1985; ISIS-1
Collaborative Group, 1986).
The precise mechanism mediating the beneficial effect of
3-adrenoceptor antagonists on sudden cardiac death remains
unclear; in particular, there is uncertainty over whether the drugs
are acting by a direct antiarrhythmic effect or via a primary
anti-ischaemic influence. Although the reduction in mortality cited
by the Miami Trial Research Group (1985) was not paralleled by a
lower incidence of ventricular fibrillation, other studies have
demonstrated significant reductions in ventricular fibrillation with
intravenous metoprolol (Ryden et al, 1983) and propanolol (Norris et
al, 1984). It is probable that any antifibrillatory/antiarrhythmic
effect of the 3-blockers is due to direct antagonism of circulating
(and neurogenic) catecholamines, since the drugs have been shown to
reverse the lowering of ventricular fibrillation threshold induced by
catecholamines in experimental models (Gillis and Clusin, 1984).
Furthermore, catecholamine concentrations are known to be
abnormally high in the acute infarction period (Richardson, 1963),
where they may be inherently arrhythmogenic by nature of the
associated increase in myocardial oxygen demand and effects on rate
and automaticity. Various metabolic factors have also been held
responsible for arrhythmogenesis in the acute infarction period and
many of these are consequent upon increased catecholamine activity
46
(Opie et al, 1979). Hypokalaemia is a particular hazard which may be
induced by adrenaline and inhibited by certain ^-adrenoceptor
antagonists (Struthers et al, 1981).
Thus the effects of catecholamines and the 3-adrenoceptor
antagonists on acute ischaemic arrhythmias must be distinguished
from their effects on chronic ventricular arrhythmias, where the
drugs are not consistently effective. It follows, therefore, that if
the reduction of sudden death afforded by the 13-adrenoceptor
antagonists is in fact due to arrhythmia prevention, then it is more
likely that the arrhythmias are of a primary, ischaemic nature,
rather than those seen with chronic ventricular ectopy.
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Changes in the effective refractory period (ERP) relative to the
action potential duration (APD) induced by different classes
of antiarrhythmic agents.
(Adapted from: Singh and Nadamanee, 1982).
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Chapter 3. EXPERIMENTAL MODELS FOR THE EVALUATION
OF ANTIARRHYTHMIC DRUGS
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So numerous are the experimental models for antiarrhythmic
drug assessment that no single classification will adequately cover
the subject without considerable overlap. One system, for example,
would be to categorize with respect to the initiating arrhythmogenic
event, e.g. drug-induced arrhythmias, mechanically or thermally-
induced, arrhythmias secondary to CNS stimulation, electrically-
induced or those resulting from experimental ischaemia. However,
since studies almost exclusively involve mammals (one exception
being the occasional use of the toad heart), another classification
would be to concentrate on the relative advantages and
disadvantages of the respective mammalian species.
The following chapter is intended to give an outline of the
differences between the various animal models and the results of
studies with drugs from the 4 antiarrhythmic classes. Unfortunately
this cannot always be complete as, until fairly recently, few class 3
or 4 agents were known and the degree to which they had been tested
in animal models was limited . Nevertheless, an attempt has been
made to include this information where possible.
3.1 Non-Canine Models
3.1.1 isolated Tissues
It has been possible for some time to culture preparations of
cardiac cells in such a way as to allow accurate recording of
pacemaker activity (Moore et al, 1981). Exposure of such
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preparations to arrhythmogenic chemicals such as ouabain or
halothane and adrenaline has subsequently allowed evaluation of
class 1 and 2 activity respectively (Miletich et al, 1983; Goshima
and Wakabayashi, 1983). It could be argued that such a model would
obviate the need for animal experimentation, but heart cell cultures
are limited in a number of ways: it is believed that any cell line has
a tendency to degenerate into a more primitive state when cultured
(Miletich et al, 1983). It has furthermore been suggested that
cultured heart cells have electrophysiological characteristics more
in keeping with pacemaker, as opposed to ventricular, cells (Schanne
and Kbaily, 1981). Finally, the study of ischaemic conditions in cell
culture preparations has been questioned for its relevance to the
clinical situation (Hearse, 1983).
Studies on isolated Purkinje fibres have allowed the accurate
determination of electrophysiological parameters such as resting
transmembrane potentials, rate of rise of the action potential,
maximum rate of depolarization and refractory periods (Weidmann,
1955; Davis et al, 1969; Rosen et al, 1973). Using such preparations,
it is possible to study the effects of drugs under physiological
conditions, as well as those of altered pH, hypoxia, and changes in
ionic concentrations (see chapter 1.1.5). Although in many respects
these preparations offer distinct advantages over the cell cultures
mentioned earlier, they are subject to similar problems; in
particular, it should be remembered that isolated tissues are
dependent upon intracellular energy stores, predominantly glycogen.
As these stores are utilized, spontaneous contractions will decline,
a phenomenon unrelated to any drug effect.
Use of the 'Langendorff isolated, buffer-perfused rat heart
does not overcome the problem of the slow decline in tissue
contractility, but provides a model where it is possible to study the
effects of ischaemia on the intact heart (Broadley, 1979; Inque et al,
1984). Using ventricular fibrillation as an endpoint, it has been
shown that the addition of class 1 drugs or verapamil to the
perfusate offers antiarrhythmic protection (Winslow, 1984);
nifedipine, however is less effective and class 2 agents do not
appear to be of benefit. Similar studies have also been employed to
create conditions of ischaemia by ligating a main coronary artery,
and this has proved suitable for a number of antiarrhythmic studies
(Lubbe et al, 1978; Inque et al, 1984).
Despite the advantages of the model or apparent efficacy of a
drug under test, results of all in vitro antiarrhythmic studies will
continue to be viewed with caution, since by their very nature they
cannot take into account factors such as neurogenic input, humeral
influences, biochemical variations, pH fluxes and alterations in
arterial gas tensions. In order to gain a better understanding of the
true milieu for antiarrhythmic efficacy therefore necessitates the
use of intact animals.
3.1.2 Rodents: the Mouse. Rat, and Guinea-Pia
i
Since rodents are relatively inexpensive, they are particularly
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suited to initial screening investigations where serial experiments
may be performed with a view to statistical evaluation. Compared
with the larger mammals, rodents have comparatively small hearts,
and this is the probable explanation for the ability of the animals to
defibrillate spontaneously. In the mouse-chloroform model the
mechanism of the arrhythmogenic effect of chloroform is not
entirely clear, but appears to involve the sensitization of the
myocardium to endogenously-released catecholamines (Moore et al,
1981). Although used to assess all classes of antiarrhythmic drugs
(Block, 1981), it has been suggested that the mouse-chloroform
model is a better indicator of {3-adrenoceptor antagonism (Moore et
al, 1981).
Infusion of aconitine nitrate into the tail vein of a mouse
produces an alternative arrhythmia model which, like the chloroform
model, has ventricular fibrillation as the end-point (Dadkar and
Bhattacharya, 1974; Nwangwu et al, 1977). The fibrillatory effect of
aconitine may be due to its cholinergic actions on the atria, although
a direct ventricular action has been suggested (Winslow, 1984). This
model appears to be selectively sensitive to drugs with class 1
antiarrhythmic action (Winslow, 1984).
The rat is another frequently used model which has the
advantage of providing suitable access for the recording of blood
pressure and drawing of venous samples (Kane and Winslow, 1980).
Following the studies of Selye et al (1960), the rat rapidly became a
standard model for the study of the arrhythmias occurring shortly
53
after coronary artery ligation where class 1, 2 and 3 agents all
appear to have offered antiarrhythmic protection (Kane and Winslow,
1980; Winslow, 1984). More recently a similar model has been
described in conscious rats (Curtis et al, 1984) and studies have
been extended to include also those arrhythmias which occur upon
release of a temporary coronary artery occlusion (reperfusion
arrhythmias) (Bergey et al, 1982). There is, however, one
fundamental problem when using the rat as an arrhythmia model in
that the rat electrocardiogram has no ST segment. Unlike most
mammals, the T wave arises immediately following the QRS complex
with no isoelectric ST phase (Spear, 1981). Since differences in
myocardial transmembrane potentials are likely to be associated
with differences in membrane ionic conductances, demonstration of
antiarrhythmic efficacy in the rat may not be predictive of a similar
action in man. It is known, for example, that doses of digitalis which
produce arrhythmias and cardiac disturbances in man have little
effect in the rat (Dutta and Marks, 1966), probably as the result of
specific differences in sodium/potassium ATPase between the rat
and man (Allen and Schwartz, 1969).
Guinea-pigs have most commonly been used as arrhythmia
models in the study of arrhythmias produced by toxic doses of
cardiac glycosides (Sekiya and Vaughan Williams, 1963; Vaughan
Williams and Sekiya, 1963; Hermansen, 1970). In this respect the
model is similar to the ouabain-induced arrhythmia in the dog in
i
being most sensitive to the actions of class 1 drugs (see chapter
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3.2.1), although the model differs in being sensitive also to the p
adrenoceptor antagonists. Like the mouse, the guinea-pig is sen¬
sitive to the effects of aconitine; although studied less widely than
the former model, results with antiarrhythmic drugs appear similar.
3.1.3 The Rabbit. Cat and Pig
Because of its quiet nature, the rabbit lends itself particularly
well to experimentation in the conscious state and for observation
by continuous ECG recording. The species has been particularly
employed for evaluating effects on nodal conduction, due primarily
to the superficial location of both the SA and AV nodes (Wit and
Cranefield, 1974). More recently it has been suggested that the
rabbit offers a reasonable alternative to rats or dogs for the study
of coronary artery occlusion/reperfusion arrhythmias, since it does
not share the electrocardiographic anomalies of the rat while at the
same time avoiding the increasing cost of canine experimentation
(Coker, 1987). Such experiments, however are relatively new and
insufficient studies have been carried out to allow a critical
appraisal of the effects of the various drug classes.
The cat has been used in the study of arrhythmias due to
hypothermia (Rashid and Alps, 1973), glycoside toxicity (Raper and
Wale, 1968), central sympathetic stimulation (DiMicco et al, 1977)
and the early and late arrhythmias of coronary artery ligation
(Ritchie et al, 1979). More recently, a chronic feline myocardial
infarction model has also been the subject of investigation
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(Myerburg et al, 1977). Of particular interest here is the
spontaneous ventricular ectopy which develops one to six months
after coronary artery ligation; since this is not a feature of other
animal models, it has prompted the suggestion that the chronic
feline may approximate more closely to the chronic ectopy seen in
man (Myerburg et al, 1977).
A number of investigators have used the pig for
electrophysiological, electropharmacological and antiarrhythmic
studies (Bergey et al, 1982; Verdouw et al, 1983; Benfey et al,
1984). A unique feature of the porcine model relates to the nature of
the coronary circulation; whereas in the dog there exists an
extensive collateral circulation, this is much less impressive in the
pig, with man occupying a position somewhere in the middle (Bergey
et al, 1982; Verdouw et al, 1983). However, there are demonstrated
differences between porcine and human Purkinje fibres, and
ventricular activation as seen in the porcine electrocardiogram is
more rapid (Moore et al, 1981).
3.1.4 Primates
As a primate, the monkey would be expected to share similar
cardiovascular features with man. Although largely true, there are
notable exceptions such as the third main coronary artery in the
baboon (Opie et al, 1983). Also the subendocardial nature of
experimental infarction in the baboon differs fron the more usual
transmural infarction in man (Flameng et al, 1986). The major
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disadvantage of using primates, however, relates to expense and the
risk of infection, particularly the 'slow' viral encephalopathies
which are invariably fatal in man (Opie et al, 1983). Also it should
not be forgotten that primates such as the baboon may be
particularly vicious and hence not well suited to experimentation in
the conscious state.
In summary, therefore, there is no single experimental model
which can accurately predict the effectiveness of a potential
antiarrhythmic agent in man. Nevertheless, for various practical and
financial reasons, it is the dog which has emerged as the most
appropriate animal for such studies and will therefore be considered
separately. Before leaving this diverse field entirely, however, spare
a thought for the unfortunate Japanese quail, which, when fed on a
2% cholesterol diet, developes severe atheroma, myocardial
infarction and arrhythmias, and then dies suddenly, and has
accordingly been introduced as a further model for sudden cardiac
death (Cheung et al, 1983).
3.2 Acute Canine Models
3.2.1 The Ouabain Arrhythmia
Ouabain is one of a number of structurally related, naturally
occurring cardiac glycosides which as a group have been shown to
decrease resting membrane potentials, decrease the maximal rate of
depolarization and overshoot of the action potential, reduce the rate
57
of repolarization, and enhance phase 4 automaticity (Rosen et al,
1973; Rosen 1985). While it is not clear exactly which of these
electrophysiological parameters is responsible for the arrhythmias
resulting from toxic doses of ouabain, experimental work has
suggested that the arrhythmias result from enhanced automaticity
(Vassalle et al, 1963; Rosen et al, 1973) with the pacemaker site
located in a left bundle branch or the Purkinje fibre network
(Damato et al, 1971). Increasing toxicity appears to be associated
with progressive enhancement of such ectopic foci, since at low
doses of the drug these changes may only be unmasked when the
sinus rate is slowed by vagal stimulation (Vassalle et al, 1963).
Again during the early stages of toxicity, the arrhythmias may be
dependent upon a fixed relationship with an initiating sinus beat.
This has raised the suggestion that the phenomenon is primarily one
of triggering (see chapter 1.2.3); however at more advanced stages
of ouabain toxicity the ventricular ectopic rhythms lose any such
relationship and runs of self-sustaining ventricular tachycardia
ensue (Vassalle et al, 1963).
The interaction between ouabain and the autonomic nervous
system is a further factor which must be considered in the
arrhythmogenic actions of the drug. Like all cardiac glycosides,
ouabain has a direct vagal effect (Hoffman and Cranefield, 1960),
but studies utilising toxic doses of the drug have indicated an
activation of sympathetic ganglia (Konzett and Rothlin, 1952) and
stimulation of central sympathetic centres (Standaert et al, 1969).
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Since enhancement of phase 4 depolarization is common to both
sympathetic stimulation and ouabain toxicity, it was initially
suggested that the arrhythmia might be dependent upon
catecholamine release (Roberts et al, 1963), but although earlier
studies with the (3 adrenoceptor antagonist pronethalol had
demonstrated antiarrhythmic efficacy (Vaughan Williams and
Sekiya, 1963), subsequent work by Lucchesi (1965) indicated that
this antiarrhythmic effect was not related to pronethalol's
P-blocking properties. Pronethalol has significant membrane-
stabilizing properties and it is this action which is thought to
account for its antiarrhythmic activity in the ouabain model (Somani
and Lum, 1965). Indeed, more recent studies with {3 adrenoceptor
antagonists devoid of class 1 activity have shown an exacerbation of
the ouabain arrhythmia (Alkondon et al, 1984). While class 1
activity may account for the efficacy of the class 3 agent
amiodarone however, it would not, explain the results with the
verapamil, a class 4 drug (Caillard and Louis, 1980).
3.2.2 The Halothane-Adrenaline Arrhythmia
It has already been mentioned how myocardial adrenergic
stimulation results in a number of potentially arrhythmogenic
electrophysiological changes, largely mediated by (3 receptors (see
chapter 1.1.5). Whilst this is rarely of clinical importance in
otherwise healthy individuals, it was recognised many years ago
that these arrhythmogenic properties could be greatly enhanced by
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prior exposure to general anaesthetic agents, often with
catastrophic consequences (Meek, 1941). It was this observation
which led to the experimental models where arrhythmias could be
produced by administering intravenous adrenaline to dogs respired
with cyclopropane (Nickerson and Nomaguchi, 1949), chloroform
(Vick, 1966) and more recently halothane (Price and Ohnishi, 1980).
Although it is believed that the arrhythmogenic effects of
adrenaline reflect its actions in enhancing phase 4 automaticity in
the conducting network (Hoffman and Singer, 1967), it is less clear
why potentiation should be apparent with anaesthetic agents: while
some such agents (eg. diethyl ether) are capable of stimulating
sympathetic outflow, others (including halothane), result in lower
levels of circulating catecholamines (Roizen et al, 1974). However,
all general anaesthetics produce direct myocardial depression by an
inherently arrhythmogenic mechanism thought to involve a reduction
in the amount of free calcium available for the contractile elements
(Price and Ohnishi, 1980).
The haemodynamic conditions pertaining at the time of
arrhythmogenesis have also been the subject of considerable debate:
it has been suggested that a pressor response to adrenaline is a
prerequisite before the emergence of the arrhythmia and may even
dictate the severity of the arrhythmia (Dresel and Sutter, 1961).
Heart rate may be similarly important: a number of early
experiments utilizing both vagal stimulation (Dresel and Sutter,
1961; Vick, 1966) and atrial pacing techniques (Dresel et al, 1960)
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demonstrated that a positive chronotropic response was necessary
before the emergence of the arrhythmia, but more recently it has
been shown that the arrhythmia may not be dependent so much upon a
tachycardia in response to adrenaline as upon an initial bradycardia
induced by halothane (Hashimoto and Hashimoto, 1972). Halothane is
known to have a negative chronotropic effect on the sinus node
which is resistant to atropine (Reynolds et al, 1970). Thus it
appears that the mechanism of sensitization by halothane to produce
multifocal ventricular ectopics and tachycardia may relate to a
slowing of sinus rate by halothane in conjunction with a pressor
response and tachycardia from the adrenaline. The ventricular
fibrillation occasionally seen is thought to be independent of heart
rate and may relate primarily to the depressant action of halothane
on the myocardium (Price and Ohnishi, 1980).
Not surprisingly, the halothane-adrenaline model has been used
extensively as an index of the (3 adrenoceptor blocking properties of
antiarrhythmic agents. However, in a recent study investigating the
effects of prazosin and metoprolol on this arrhythmia, it was
discovered that p-j blockade from metoprolol was significantly less
effective than a-\ blockade afforded by prazosin (Maze and Smith,
1983); nor was the effect of prazosin related solely to
haemodynamic consequences as sodium nitroprusside was found to
be ineffective in abolishing the same arrhythmia despite producing a
similar fall in blood pressure and attenuating the pressor response
to adrenaline. Calcium channel blockers have also been found
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effective in this model, although variable reports have resulted from
the testing of class 1 agents (Shibuya et al, 1963).
3.2.3 The Early and Late Arrhythmias of Coronary Artery
Ligation
The first example of experimental coronary artery ligation
may date as far back as 1698 when Chirac was reported to have tied
the coronary artery of a dog (Porter, 1894). The animal, however,
died shortly afterwards and since the physicians of the day had
little appreciation of the importance of the coronary vasculature,
interest remained quiescent until Erichsen (1842) reported the
effects of coronary artery ligation on heart rate and rhythm. This
was followed by a number of similar experiments in various animal
species, but it was not until 1918 that the results of such
manoevres could be corroborated with simultaneous
electrocardiographic recording (Smith, 1918). These and subsequent
investigations have shown that acute occlusion of a major coronary
artery is associated with a high incidence of severe ventricular
arrhythmic activity and death within the first few minutes of
occlusion (Dreifus et al, 1981). More recently, 2 distinct periods of
maximal activity have been identified (Kaplinsky et al, 1979):
immediate ventricular arrhythmias (IVA, or 1a) occur from 2-10 min
after coronary occlusion and are thought to relate to reentrant
mechanisms in the subendocardial region of the ischaemic zone
(Kaplinsky et al, 1979). Delayed ventricular arrhythmias (DVA, or 1b)
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occur from 12-30 min after ligation; while they, too, are probably
dependent on reentry , experimental evidence has suggested that the
mechanisms may not parallel those responsible for the immediate
arrhythmias (Menkin et al, 1979; Russell et al, 1984).
Following the discovery that coronary artery ligation in
conscious dogs was associated with a mortality of up to 3 times
that seen in anaesthetised animals (Manning et al, 1939), McEachern
and coworkers (1940) demonstrated that prior thoracic
sympathectomy could reduce mortality in conscious dogs from 75%
to 10%. Furthermore, it has been shown that similar reductions in
mortality (unrelated to the area of infarction) can be observed after
cardiac denervation in anaesthetised dogs if sufficient time is
allowed for myocardial catecholamine depletion, emphasizing the
role of both endogenous and neurogenic catecholamines in the
genesis of the acute arhythmias (Ebert et al, 1970). Alpha
adrenoceptor antagonists have proved successful in attenuating
these arrhythmias in a number of models (Sheridan et al, 1980;
Penny and Sheridan, 1982; Benfey et al, 1984) and similar results
(although less dramatic) have been obtained with at least one of the
(3 adrenoceptor antagonists (Gamble and Cohn, 1972). Using various
manipulations of the basic acute model, various investigators have
reported benefit from the use of procainamide and quinidine
(Stephenson et al, 1960), bretylium (Kniffen et al, 1975), aprindine
(Verdouw et al, 1977), lignocaine (Gamble and Cohn, 1972) and
verapamil (Fondacaro et al, 1978). However, the relative advantages
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of each of these drugs is fairly small and none appears optimally
protective, possibly due to the variable incidence of ventricular
fibrillation within any group under study (Dreifus et al, 1981).
Since the major determinant of infarct size is the period of
time during which tissue is rendered anoxic, reperfusion of the area
of myocardium at risk has for some time been a primary goal of
many cardiologists. It is interesting, therefore that while (from an
arrhythmia point of view) this is a fairly safe procedure clinically
(Witkowski and Corr, 1984), in experimental models reperfusion
after a variable period of coronary artery occlusion is associated
with serious ventricular arrhythmias (Battle et al, 1974) and is now
included as one of the most malignant arrhythmia models (Dreifus et
al, 1981). Although evidence suggests that reperfusion arrhythmias
share the same reentrant basis as the arrhythmias of acute
ischaemia (Scherlag et al, 1970), it has been postulated that the
site of origin of the arrhythmias may not be the same in both models
(Agarwal et al, 1984). In general, drugs with a adrenergic blocking
properties or class 1 activity appear to be most useful in controlling
the arrhythmias associated with reperfusion; class 4 drugs have
also been favourably reported but p adrenergic blockade does not
appear to be protective (Sheridan et al, 1980; Brooks et al, 1980;
Dreifus et al, 1981; Thandroyen et al, 1983; Winslow, 1984).
In 1950, Harris noted "previous experimental studies on
ventricular ectopic activity following coronary occlusion ... have
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been confined to observations made within a brief acute period after
occlusion ... The scarcity of experimental studies upon the delayed
development of ventricular arrhythmias ... is attributable in part to
the high rate of early mortality via ventricular fibrillation which
results from abrupt occlusion ... of the left coronary artery." The
subsequent description of Harris's two-stage ligation allowed the
identification of a 'late' ventricular arrhythmia which has been
regarded for many years as one of the most valuable experimental
arrhythmia models.
The technique originally described involved the application of
a critical stenosis, or partial occlusion, of the left anterior
descending coronary artery, followed 30 minutes later by complete
occlusion. Any acute arrhythmic activity was noted to cease totally
within 4 hours, but around 8 hours a second arrhythmic phase began
which peaked at 24-48 hours and subsided completely by the fourth
day (Harris, 1950). The arrhythmia itself is characterized by a rapid
multifocal ventricular tachycardia interspersed with occasional
sinus beats; it is of note that ventricular fibrillation is not a
feature of this particular model.
The origin of the '24 hour' arrhythmia is thought to arise from
enhanced automaticity in surviving subendocardial fibres (Friedman
et al, 1973; Scherlag et al, 1974; Horowitz et al, 1976). Evidence for
the automatic nature of the arrhythmia has been demonstrated by
overdrive pacing techniques (Scherlag et al, 1974; Horowitz et al,
1976) and it is interesting to speculate on the observation that the
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arrhythmia may be entirely absent in dogs which are particularly ill
postoperatively (Harris, 1950); presumably this relates to a form of
overdrive suppression by a rapid sinus node discharge rate.
It has been suggested that drugs from each of the
antiarrhythmic classes are effective to a greater or lesser degree in
abolishing the arrhythmia occurring 24 hours after coronary ligation
in dogs (Caillard and Louis, 1980; Dreifus et al, 1981; Winslow,
1984). Although some have postulated that the arrhythmia may be
subject to autonomic control (Martins, 1985), studies with a
agonists and antagonists have shown little effect (Constantin and
Martins, 1987) and results with p adrenoceptor blockade remain
equivocal; moreover, as with the ouabain-induced arrhythmia,
reported benefit from the use of p adrenoceptor antagonists may
relate primarily to class 1 activity (Allen and Shanks, 1974;
Hashimoto et al, 1982).
It has been suggested that this particular arrhythmia model
may resemble the sequence of events seen after acute myocardial
infarction in man (Davis et al, 1982). Survival of subendocardial
Purkinje fibres after infarction has been demonstrated in man
(Fenoglio et al, 1976) but although this may be a site of arrhythmia
genesis, the essentially benign nature of the experimental model
distinguishes it from the clinical situation.
Finally a number of alternative methods have been described
for the production of experimental myocardial ischaemia and/or
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infarction. These include the use of ameroid constrictors upon, or
balloon occluders within, the coronary vasculature (Coltart et al,
1974; Rosenfeld et al, 1978) and the radiologically-guided
introduction of an occluding bead or beads into the appropriate
coronary vessel (Wilkerson and Downey, 1978; Karagueuzian et al,
1982). While some of these methods may allow the study of acute
myocardial ischaemia in the conscious animal, there does not appear
to be any advantage in studies of the '24 hour' arrhythmia. Indeed,
without the facility of direct inspection of the coronary
vasculature, it would be difficult to assess the degree of collateral
circulation in deciding a point of occlusion.
3.2.4 The Adrenaline-Induced Arrhythmia. 3-5 davs after
Coronary Artery Ligation
While there may be controversy over the role of sympathetic
factors in the arrhythmia occurring 24 hours after coronary ligation,
it has been demonstrated that the infarcted myocardium is more
sensitive to the effects of exogenously administered adrenaline for
several days after ligation. Thus adrenaline, in doses which cause
minimal effects on rhythm in normal dogs, is capable of producing a
prolonged ventricular tachycardia in post-infarcted animals (Maling
and Moran, 1959). More recently, studies with isolated Purkinje
fibres 24 hours after infarction have confirmed this enhanced
sensitivity to the arrhythmogenic effects of adrenaline, particularly
in fibres from the infarcted areas (Cameron et al, 1982).
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In their original study, Maling and Moran (1959) concluded that
the factors necessary for the production of the arrhythmia included
direct stimulation of the myocardium and an associated slowing of
sinus rate. This explains the arrhythmogenic actions of agents such
as adrenaline and noradrenaline while isoprenaline, despite its
stimulant properties, increases the sinus rate both directly and
secondary to the fall in blood pressure, and is ineffective in
establishing the arrhythmia. In many respects, therefore, the model
has similar characteristics to the halothane-adrenaline model,
although it may be argued that the latter is not as relevant to the
clinical situation as the conscious, post-infarcted animal with a
high circulating catecholamine load. A summary of the factors
thought to be necessary for arrhythmia genesis in the respective
adrenaline-induced arrhythmia models is given in figure 3.1.
Although not studied as widely as the halothane-adrenaline
model (there are no records of experiments investigating class 3 or
4 drugs), the adrenaline-induced arrhythmia after coronary artery
ligation appears to share the same features when used as a test of
antiarrhythmic activity. Thus the greatest efficacy has been
demonstrated with the (3 adrenoceptor antagonists, while class 1
agents in general appear ineffective (Allen et al, 1974).
3.3 Chronic Canine Models
3.3.1 The History of Electrophysiological Studies
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The first recorded experiment which investigated the effects
of electricity on the heart appears to have been in the 1700's when
Abilgard shocked a chicken lifeless using current stored in a Leyden
jar (Abilgard, 1775). In 1889 two Swiss physiologists, Prevost and
Battelli, demonstrated that electric currents produced ventricular
fibrillation when applied directly to the heart (Prevost and Battelli,
1889). It is of note that the reciprocal finding of resuscitation by
similar electric shocks was added only as a footnote. Such studies
laid the foundation for what remains to this day a valuable
electrophysiological investigation, ie. the ventricular fibrillation
threshold (VFT).
The VFT requires the application of electric current (either as
a single, critically timed pulse or as a train of pulses) to the
ventricular myocardium during the vulnerable period of recovery
from a previous depolarization (Moore and Spear, 1975). The
fibrillation threshold value (the minimum intensity of current
required to produce ventricular fibrillation) is considered to be an
index of ventricular vulnerability to fibrillation, and the ability of
test agents to elevate this threshold is generally accepted as an
indication of potential antiarrhythmic activity (Lynch and Lucchesi,
1987). It is well established that the VFT is lowered during acute
myocardial ischaemia and infarction, reflecting the greater
propensity of the ischaemically injured heart to fibrillate. In a
recent study with chronic post-infarction dogs, a reduction in VFT
was found in those animals with inducible sustained ventricular
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tachycardia (Gang et al, 1982), suggesting a link between traditional
measures of ventricular vulnerability to fibrillation and the
inducibility of ventricular arrhythmias by programmed electrical
stimulation.
\
3.3.2 Programmed Electrical Stimulation in Chronic Canine
Models of Myocardial Infarction
Until fairly recently, it was believed that since animals did
not exhibit spontaneous ventricular ectopy much later than 3-4 days
after experimental coronary artery occlusion (an exception being the
cat-see chapter 3.1.3), a suitable chronic model of myocardial
infarction did not exist. However, in a series of studies in dogs,
El-Sherif and co-workers were able to demonstrate delayed,
slowly-conducting electrical activity within areas of damaged
myocardium, 3 to 5 days after experimental coronary artery
occlusion (El-Sherif et al, 1977 (a),(b)). When such activity became
continuous, as occurred during rapid pacing or with the induction of
appropriately timed premature beats, runs of ventricular
tachycardia ensued, prompting the authors to suggest a reentrant
basis. It is interesting that similar observations had previously been
made in acute canine myocadial infarction models (Waldo and Kaiser,
1973; Boineau and Cox, 1973) and were subsequently to be confirmed
clinically (Josephson et al, 1978 (a),(b)).
At around the same time as these observations were made, a
number of independent investigators were able to demonstrate
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induction of ventricular tachyarrhythmias in post-infarcted dogs
when challenged with programmed electrical stimulation (Glassman
et al, 1978; Karagueuzian et al, 1979; Michelson et al, 1980(a);
Garan et al, 1980; Gibson and Lucchesi, 1980; Patterson et al, 1980).
These experiments were all based on the finding that in the
post-infarcted canine heart, electrical stimuli subthreshold for
ventricular fibrillation could more easily induce ventricular
tachyarrhythmias when delivered as two or more closely coupled
stimuli (Thompson and Lown, 1972). Furthermore, more recent
studies have shown that the addition of a second and third
extrastimuli will also result in a progressive shortening of
refractoriness, permitting the propagation of ectopic beats much
earlier during the cardiac cycle than can be achieved with one
extrastimulus alone (Moore et al, 1986).
Following the earlier finding that release of a coronary artery
occlusion after a period of 40 minutes to 3 hours was capable of
salvaging 'islands' of surviving myocardium (Maroko et al, 1972;
, Ginks et al, 1972; Reimer et al, 1977), a number of investigators
now routinely include reperfusion in their surgical protocols. This is
based on the proposal that these areas of surviving myocardium
offer a better substrate for the genesis of reentrant pathways,
although with the exception of one trial (Karagueuzian et al, 1979)
this does not appear to have been studied under controlled
conditions.
To date, numerous antiarrhythnic agents representing the
71
various classes of antiarrhythmic drug action have been evaluated in
chronic coronary artery occluded or occluded/reperfused
preparations, either in the conscious or anaesthetised state. The
efficacy of these agents in suppressing the arrhythmias induced by
programmed electrical stimulation is summarized in tables 3.1 and
3.2. In general, class 1 agents have been only marginally effective in
suppressing these arrhythmias; in fact, several studies have shown
significant proarrhythmic effects (Patterson et al, 1980; Patterson
et al, 1982 (a); Zimmerman et al, 1985; DiCarlo et al, 1985) (also
see chapters 3.3.4 and 11.3). The effects of beta-adrenergic
antagonists have varied widely with the agent under test: results
with metoprolol and nadolol have been disappointing, while
propanolol, timolol and sotalol have each demonstrated significant
antiarrhythmic activity (see table 3.1). Variable results, too, have
been reported with the class 3 agents, although this may in part be
due to the lack of a 'pure' class 3 drug, devoid of ancillary
electrophysiological effects (Lynch and Lucchesi, 1987). Results
with class 4 drugs tend to suggest that the calcium antagonists are
ineffective in these models (see table 3.2).
Programmed electrical stimulation in man was originally
introduced as a means of studying the electrophysiological events
associated with ventricular tachycardia (Wellens et al, 1972,1974).
Subsequently it has been employed as a means of directing drug
therapy in the management of patients with recurrent ventricular
arrhythmias (Bigger et al, 1982; Podrid et al, 1983; Echt and Mason,
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Drug Preparation Effects on Induced VT
Lignocaine (i) C/R 0/8 suppressed:VT rate slowed
(ii) (A+C)/R VT facilitated
Procainamide (i) A/R 5/9 suppressed: VT rate slowed
(ii) C/R 0/5 suppressed: VT rate slowed
Phenytoin A/O 2/10 suppressed: VT rate slowed
Quinidine C/R 4/8 suppressed: VT rate slowed
Encainide C/R 0/5 suppressed
Flecainide (i) A/R 1/9 suppressed: Proarrhythmic effects
(ii) A/R 0/7 suppressed: VT facilitated
Propanolol (i) C/R 5/5 suppressed
(ii) A/R 9/15 suppressed
Timolol A/R 13/22 suppressed
Metoprolol C/R 1/14 suppressed: VT rate unchanged
Sotalol (dl) C/R 5/9 suppressed: VT rate slowed
(I) C/R 10/14 suppressed: VT rate slowed
(d) C/R 13/22 suppressed: VT rate slowed
Nadolol C/R 0/7 suppressed: VT rate unchanged
Table 3.1
Programmed Electrical Stimulation in Chronic Canine Models of Myocardial Infarction:
1. Effects of Class 1 and 2 Drugs.
(Key: A, anaesthetised: C, conscious: VT, ventricular tachycardia
O, occlusion: R, occlusion/reperfusion.)
(Adapted from: Lynch and Lucchesi, 1987)
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Drug Preparation Effects on Induced VT


















0/5 suppressed: VT rate unchanged
0/6 suppressed: VT rate unchanged
0/7 suppressed: Proarrhythmic effects
4/12 (low dose): 9/19 (high dose)
Table 3.2
Programmed Electrical Stimulation in Chronic Canine Models of Myocardial Infarction:
2. Effects of Class 3 and 4 Drugs.
(Key: A, anaesthetised: C conscious: VT, ventricular tachycardia
O, occlusion: R, occlusion/reperfusion.)
(Adapted from: Lynch and Lucchesi, 1987)
1984; Kim et al, 1986).
Numerous studies have utilised various programming
techniques in an effort to predict those at risk of sudden death after
myocardial infarction. While some have found programmed
stimulation of valuable prognostic significance (Horowitz et al,
1978; Swerdlow et al, 1983; Stevenson et al, 1985; Waspe et al,
1985), others have questioned its applicability (Marchlinski et al,
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1983). Furthermore, it remains unclear if inducibility of
arrhythmias by programmed stimulation might not be an independent
risk factor (Friedman and Yusuf, 1986). Roy and coworkers (1985(a))
studied the use of programmed stimulation as a guide for
pharmacological therapy in survivors of cardiac arrest (a group at
high risk of recurrent sudden death). Results indicated a 12%
recurrence rate (9-20 month follow-up) compared with 48% in
patients treated empirically. However, in the same studies up to 40%
of patients failed to respond to stimulation; recurrence of sudden
death in these non-responders was as high as 32% (Roy et al, 1985
(b)). Thus in a significant proportion of survivors of cardiac arrest,
programmed stimulation alone will be ineffective in identifying risk
and guiding therapy.
3.3.3 The Conscious Canine Model of Sudden Death
In 1982, Lucchesi and co-workers described a chronic canine
model of myocardial infarction which reliably responded to an
additional ischaemic insult at a distant site with the development
of ventricular fibrillation (Patterson et al, 1982 (b)). The procedure
involved the insertion of a silver wire electrode into the lumen of
the left circumflex artery at the same time as the left anterior
descending artery was subjected to a 2-hour occlusion followed by
reperfusion. After electrophysiological testing and programmed
stimulation on the third or fourth postoperative day an anodal
current of 150mA is applied to the wire. This results in a sequence
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of events, induing arterial intimal damage, platelet aggregation,
oscillations of blood flow, electrocardiographic evidence of
ischaemia and, ultimately, the development of ventricular
fibrillation in over 90% of cases (Wilber et al, 1985). It is notable
that similar ischaemic insults in dogs without antecedent
infarctions, while in many cases resulting in posterolateral
infarctions, do not generally result in ventricular fibrillation
(Patterson et al, 1982 (b)). This suggests that lethal arhythmias are
more likely to arise in peri-infarcted tissues, electrically deranged
by the infarction process and rendered more sensitive to the effects
of ischaemia, a point made previously in a similar chronic canine
model (Kabell et al, 1984).
3.3.4 Proarrhvthmic Effects of Antiarrhythmic Drugs
Despite the demonstrated efficacy of many antiarrhythmic
drugs in suppressing ventricular ectopy, we have already seen that
this may not be paralleled by a reduction in the incidence of sudden
death. Indeed, a number have studies have shown that between 30
and 60 per cent of patients resuscitated from cardiac arrest have
been taking antiarrhythmic drugs at the time of arrest (Liberthson
et al, 1974; Moss et al, 1977; Ruskin et al, 1983). The ability of
antiarrhythmic drugs to exacerbate or induce arrhythmias has been
considered since it was first shown that syncopal attacks during
quinidine treatment might be related to paroxysms of ventricular
flutter or fibrillation (Selzer and Wray, 1964). However, direct
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evidence has been difficult to obtain because of the inherent
unpredictability of many arrhythmias.
In a retrospective analysis of antiarrhythmic drug action,
Velebit et al (1982) assessed 24-hour Holter monitoring and
maximal exercise stress testing in 155 consecutive patients
referred because of ventricular arrhythmias: in a total of 722 drug
tests, a worsening of arrhythmia (defined as the occurence of a
four-fold increase in the frequency of ventricular premature
complexes, a ten-fold increase in repetitive forms, or the first
emergence of sustained ventricular tachycardia coincident with the
time course of action of the drug under study) was observed in 80, or
11.1%. Exacerbation was apparent with each of the 9 drugs studied
(quinidine, procainamide, disopyramide, propanolol, metoprolol,
aprindine, mexiletine, tocainide and pindolol) and it is significant
that blood concentrations of the drugs were consistently within the
therapeutic range.
It has already been mentioned (chapter 1.2.3) how the genesis
of a reentrant circuit is dependent upon a critical balance of
conduction and refractoriness. Thus it may be seen how a drug with a
preferential effect on one of these parameters (eg. conductivity)
might suppress arrhythmias in one situation (by extinguishing
slowly-moving wavefronts in a reentrant pathway) while
exacerbating arrhythmias in another (by sufficiently slowing the
wavefront of depolarization to allow recovery within a reentry
pathway). In the case of the local anaesthetic agents, it has been
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shown that the effects of lignocaine on ischaemic myocardial fibres
may be different from its effects on normal areas (Allen et al,
1978), and this may predispose to local block of impulse propagation
and fractionation of the wavefront, leading to the creation of
multiple reentrant circuits (Hoffman and Dangman, 1986).
The same arguments used above with respect to conduction
may also be employed when considering refractoriness: thus while
prolongation of the refractory period may abort reentrant circuits by
rendering refractory those tissues which constitute the abnormal
pathway, the same electrophysiological effects may allow the
propagation of the wavefront by an alternative, more slowly-
recovering area of myocardium. In particular, this may explain the
possible proarrhythmic effects of the class 1a and class 3 drugs.
Special mention should also be made of the proarrhythmic effects of
the class 1c agents flecainide and encainide (Winkle et al, 1981;
Olsson and Edvarsson, 1981). These drugs have shown inordinate
propensity to convert ventricular ectopy to sustained arrhythmias
and even ventricular fibrillation. Furthermore, in many cases the
resulting arrhythmias may be remarkably resistant to defibrillation
(Winkle et al, 1981; Duff et al, 1982).
Another potentially proarrhythmic electrophysiological drug
action is prolongation of the QT interval, which has been shown to
lead to ventricular tachycardia and torsade de points (Khan et al,
1981).This is particularly likely to occur with inhomogeneous
prolongation of the action potential duration, such as occurs with
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the class 1a drugs, and is compounded in conditions in which drug
delivery and uptake varies from region to region as the result of
disease processes (Goldstein et al, 1984).
Other possible arrhythmogenic effects of drugs may not
necessarily be related to electrophysiological properties.
Anticholinergic effects of drugs such as quinidine and disopyramide
are known to favour ventricular electrical instability in the
presence of ischaemia (Goldstein et al, 1973), and reflex
sympathetic stimulation might be expected of any drug with
negative inotropic activity. Negative inotropes themselves may be
inherently proarrhythmic by exacerbating cardiac failure and such
deleterious haemodynamic effects may also prejudice recovery from
ventricular fibrillation (Euler et al, 1986).
Many of the early proarrhythmic studies used either Holter
monitoring or exercise stress-testing with an increase in the
number of ventricular ectopic beats as an end-point. However, recent
evidence suggests that in some cases invasive electrophysiological
testing may unmask latent proarrhythmic effects which are not
apparent with simple electrocardiographic monitoring (DiBianco et
al, 1982). In one study (Duff et al, 1982) chronic ventricular ectopy
(as assessed by ambulatory monitoring) was actually improved by
the same drug (encainide) which demonstrated proarrhythmic
effects with programmed electrical stimulation. Furthermore, with
electro- physiological testing, a defined inducible arrthythmia
serves as the basis for comparing all subsequent results, drug
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exposure is brief, blood levels are defined throughout and adverse
effects can be treated appropriately and promptly (Goldstein et al,
1984).
A summary of some of the larger clinical studies which have
used programmed electrical stimulation as an investigational tool
for evaluating proarrhythmic responses to antiarrhythmic drugs is
given in table 3.3. It can be seen that most of these studies have
involved the class 1a and 1c drugs, although results are available for
class 1b (Poser et al, 1985), class 2 (Poser et al, 1985), class 3
(Rae et al, 1985) and class 4 (Torres et al, 1985).
In a thorough study of 181 patients referred because of a
variety of ventricular arrhythmias, Torres et al (1985) discontinued
all drugs and found that ventricular tachycardias (VT) could be
induced by programmed stimulation in all patients. After subsequent
drug dosing, a proarrhythmic response was defined as:
(a) spontaneous development of VT coincident with the
administration of the drug.
(b) a reduction in the number of stimuli needed to induce VT.
(c) development of sustained VT where only non-sustained VT had
previously been induced.
(d) VT requiring cardioversion which previously had terminated
spontaneously or with burst pacing.
(e) Induction of VT after drug dosing when previously no VT had been
induced.
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Reference Drug Arrhythmia Criteria for Positive
History Proarrhythmic Results
Response
Duff et al (1982) E History of NS-VT Enhanced ease of induction 4/6
DiBianco et al (1982) E Frequent VPC's Induction of VT 3/20
Rinkenberger et al (1982) D,A,E,Q History of NS-VT Conversion to S-VT 11/83
Ruskin et al (1983) Q,D Survivors of VF Induction of VT 4/6
Poser et al (1985) Various History of NS-VT Conversion to S-VT 3/216t
Fewer stimuli for NS-VT (trials)
Rae et al (1985) Various Inducible VT Conversion S-VT to VF 25/384
or NS-VT to S-VT (trials)
Torres et al (1985) Various Inducible VT Various (see text) 43/181
Buxton & Josephson (1986) Various Inducible NS-VT Conversion to S-VT 6/3 6
Au et al (1987) Q,D,P Frequent VPC's Induction of VT 6/24
tDrug testing with multiple agents caused aggravation of arrhythmia in 19/63 patients.
Table 3.3
Results of previous proarrhythmic studies with
programmed electrical stimulation in patients.
(Key: E, encainide: D, disopyramide: A, amiodarone: Q, quinidine: P, procainamide.
VF, ventricular fibrillation: S-VT, sustained ventricular tachycardia.
NS-VT, non-sustained ventricular tachycardia: VPC, ventricular premature beat.)
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It is notable that the authors conclude "there appears to be no
way of predicting which patients will have an arrhythmogenic
response to a given drug". In particular, for the group as a whole,
there were no significant changes in the PR interval, QRS duration,
QTC or refractoriness. Also, despite a range of proarrhythmic
effects from 28% for ethmozine to 8% for procainamide and bepridil,
further analysis showed no statistical difference between the drugs
tested.
In a study which confirmed a proarrhythmic response in 6 of
24 patients tested, Au et al (1987) found that these patients did not
differ significantly from the other 18 except with respect to
refractory periods which tended to be shorter, and the incidence of
digoxin usage which was significantly higher in the proarrhythmic
group. The latter finding may be of particular interest since
digitalis- related compounds had been implicated as having
proarrhythmic potential in earlier studies, both clinical (Moss et al,





Possible explanation for the arrhythmogenic actions of adrenaline in
anaesthetised dogs respired with halothane and in conscious dogs
following experimental coronary artery occlusion (CAL). In the former,
sinus slowing is produced by a direct effect of halothane on the sinus node;
in the conscious dog following CAL, sinus slowing is secondary to the




All experimental animal work described in the following
chapters was carried out in accordance with, and under the
jurisdiction of, the appropriate Government legislation. During his
tenure of a DHSS (Nl) Research Fellowship, the author was in receipt
of animal license types A, B, C, E and EE.
Without exception, all experiments involved the use of healthy
adult greyhounds (both sexes) cared for at the Queen's University




Observation were made in adult greyhounds of both sexes. The
dogs were anaesthetized by the intravenous administration of
sodium pentobarbitone (30 mg/kg), intubated and ventilated with
room air at a rate of 18/min and tidal volume of 13 ml/kg/min
(Palmer Ideal Pump). Lead II of the electrocardiogram (ECG) and
arterial pressure (recorded by means of a cannula in the femoral
artery) were simultaneously displayed on an oscilloscope screen and
recorded on a Lectromed LX 216 2-channel recorder. An additional
cannula in the femoral vein served for the administration of drugs.
The right vagus nerve was exposed in the neck and divided between
ligatures. A bipolar electrode was applied to the distal end of the
nerve, which was stimulated for periods of 10 sec with shocks of 1
msec duration at a frequency of 25 Hz and a voltage sufficient to
cause maximal slowing of the heart rate without loss of sinus
dominance (0.2-3.5 V). Ventricular tachycardia was produced by the
intravenous administration of ouabain 40 pg/kg, followed 15 min
later by 20 pg/kg and then 10ug/kg every 15 min until a ventricular
arrhythmia was produced. Stimulation of the vagus nerve with the
previously established voltage was repeated to confirm the
ventricular origin of the arrhythmia, (figure, over). With the
arrhythmia established for 10
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min, increasing intravenous doses of drug(s) were administered until
either the return of sinus rhythm or the death of the dog. An example
of the ouabain-induced arrhythmia is given in figure 4.1.
CONTROL OUABAIN 60ug/kg
corresponds to stimulation of the right vagus nerve.
Halothane-adrenaline arrhythmias
Adult greyhounds were anaesthetized by the intravenous
administration of pentobarbitone (30 mg/kg). Ventilation,
measurement of blood pressure and electrocardiographic recording
was similar to the methods employed for the ouabain-induced
arrhythmia. Following preparation, halothane was introduced at a
concentration of 1% in room air. After 15 min, increasing doses of
adrenaline were administered from 0.4 p.g/kg at 0.4 jig/kg
increments; these were continued at 10 min intervals until the
production of ventricular tachycardia or multifocal ventricular
ectopic beats .(figure 4.2). If ventricular fibrillation occurred,
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halothane administration was discontinued and an external DC
counter shock was applied (50-100 Joules: Pantridge Defibrillator
type 280) (figure 4.2). Halothane was then reintroduced and the
protocol continued with a lower dose of adrenaline after a 15 min
period. After determination of a test dose of adrenaline which could
produce a similar, severe arrhythmia on 2 successive occasions,
increasing doses of drug(s) were administered at 10 min intervals. 5
min after each dose of the drug(s) under study, the dog was
rechallenged with the test dose of adrenaline. The experiment
continued until the test dose of adrenaline failed to produce any
ectopic response.
Arrhythmias following acute coronary ischaemia
Adult greyhounds were anaesthetized by the intravenous
administration of sodium methohexitone (10 mg/kg), intubated and
respired with a 1.5% concentration of halothane in room air. Lead II
of the electrocardiogram and blood pressure (recorded by means of a
cannula in the femoral artery) were monitored continuously on a
Lectromed LX 216 2 channel recorder. Following thoracotomy, the
fourth or fifth left rib was dissected free and removed and the heart
exposed. The anterior descending branch of the left coronary artery
was then dissected free and a ligature passed loosely behind the
artery. After a 5 min control period the .dog was randomly allocated
to receive intravenous placebo or drug(s). Five min later a critical
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stenosis of the artery was produced by tying the ligature tightly
around the artery and a 21-gauge needle, which was then withdrawn.
Following ligation, the total number of ventricular ectopic beats
were counted at 5 min intervals over a 30 min period. An example of
these arrhythmias is given in figure 4.3.
Arrhythmias 24 hours after acute coronary artery ligation
Coronary artery ligation was performed in a similar manner to
that already described for the arrhythmias of acute coronary
ischaemia, except that 30 min after coronary artery ligation a
second ligature was tied tightly around the artery (Harris, 1950).
The chest was subsequently closed in layers and the dog allowed to
recover.
Further observations were made on the consious dog 24 hours
after surgery. The dog was rested on its left side and remained in
this position thereafter. Lead II of the ECG and arterial pressure
(recorded by means of a cannula in the femoral artery) were
recorded throughout the duration of the experiment. Having ensured
that at least 80% of beats were ventricular in origin, increasing
doses of drug(s) were administered through a cannula in a foreleg
vein at 5 min intervals. This was continued until either sinus rhythm
was restored or side effects became apparent. An example of this
arrhythmia is given in figure 4.4.
Adrenaline-induced arrhythmias 3-5 davs after coronary artery
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ligation
Coronary artery ligation was performed in a similar manner to
that already described.
Further observations were made on the conscious dog, 3-5 days
after surgery. Positioning, measurement of blood pressure and
electrocardiographic recording was similar to that described for the
arrhythmia 24 hours after coronary artery ligation. After 10 min a
dose of 10 pg/kg of adrenaline was administered intravenously and
the ectopic response noted. If ventricular tachycardia or multifocal
ventricular ectopic beats did not result, adrenaline administration
was repeated after 10 min at a dose of 20 pg/kg. Having
demonstrated an adequate arrhythmia in response to the adrenaline
on 2 successive occasions, increasing doses of drug(s) were
administered at 10 min intervals. 5 min after the dose of drug(s)
under study, the dog was rechallenged with the test dose of
adrenaline. The experiment continued until the test dose of
adrenaline failed to produce any ectopic response or side effects
became apparent. An example of this arrhythmia is given in figure
4.5.
With both the ouabain arrhythmia and the arrhythmia occurring
24 hours after coronary artery ligation, the ventricular rate was
obtained by counting the number of sinus and ectopic beats in each
successive 5 min period. For the halothane-adrenaline arrhythmia
and the adrenaline-induced arrhythmia after coronary artery
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ligation, the ectopic response was determined by counting the
number of ventricular beats in the 5 min period following the test
dose of adrenaline. In all cases, sinus beats were defined before the
production of the arrhythmia. Beats with a distinct P wave preceding
a mean frontal QRS vector of normal duration were defined as being
of sinus origin; all others were denoted as ectopic.
4.2 Chronic Models
4.2.1 Surgical Procedure
Adult greyhounds of both sexes were anaesthetized by the
intravenous administration of methohexitone sodium (10 mg/kg) and
respired with 1.5% halothane and room air through an endotracheal
tube using a tidal volume of 13 ml/kg and ventilation rate of 18 per
min (Palmer Ideal Pump). Following thoracotomy, the fourth or fifth
left rib was dissected free and removed, and the heart exposed. The
anterior descending branch of the left coronary artery was dissected
free below its second branch and ligated in two stages in a manner
similar to that described above (section 4.1). Myocardial pacing
wires (Medtronic 6400 temporary myocardial pacing leads) were
sutured into the heart: one in the centre of the area supplied by the
ligated artery and a second in the area jointly supplied by an
adjacent branch of the anterior descending artery. Interelectrode
distance was maintained at 1.0-1.5 cm in all cases. This is
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illustrated in figure 4.6: the upper picture shows the exposed heart
with the left anterior descending (LAD) coronary artery coursing
down the left margin. In the lower picture a ligature has been passed
around the origin of the apical branch of the LAD and pacing wires
have been placed as described.
Both pacing wires were then brought out through skin anterior
to the thoracotomy, the wound was closed in layers and the dog was
allowed to recover. Routine antibiotic prophylaxis (250 mg
Streptomycin and 300,000 iu Procaine Penicillin) was given
intramuscularly for 3 days.
4.2.2 Protocol for Programmed Electrical Stimulation
Further observations were made on the conscious dogs, 7 to 30
days after coronary artery ligation. The dogs were positioned on
their left side and remained in this position throughout the duration
of the experiment. The myocardial pacing wires were attached to a
Digitimer 4279 modular pacing system; leads II and III of the
electrocardiogram and blood pressure (recorded by means of a
cannula in the femoral artery) were continously displayed on a
Devices MX4 polygraph. Drugs were administered by injection
through a catheter in a foreleg vein.
Our stimulating protocol is based on that described by
Lucchesi and coworkers (Wilber et al, 1985). Using bipolar pulses of
4 msec duration at twice diastolic threshold, ventricular pacing (S-|)
was introduced with a basic cycle length of 350 msec (170 beats per
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min). Burst pacing was then performed at rates of 200, 250, 300,
350, 400 and 450 beats per min, each for 5 seconds. If this failed to
produce any arrhythmia the basic cycle length was again set at 350
msec and was not altered thereafter. An extrastimulus' (S2) was
then introduced with a delay of 350 msec after the eigth basic
pacing stimulus. This delay was subsequently reduced at 20 msec
intervals until the extrastimulus failed to produce a ventricular
response (F^)- S2 was then set at the shortest delay which produced
a ventricular response, and S3 introduced with a delay of 350 msec
after S2. The procedure was repeated with S3 and S4 until an
arrhythmia was produced or the the protocol was exhausted. Figure
4.7 illustrates the equipment used and practical set-up in the
laboratory: the upper picture shows the post- operative dog while in
the lower picture the author operates the polygraph (shown on left)
and modular pacing system (shielded).
The outcome of this procedure is that the dog may be described
as 'inducible', where we achieve either a sustained ventricular
tachycardia (S-VT, defined as a self-perpetuating arrhythmia of
more than 5 mins duration) or non-sustained ventricular tachycardia
(NS-VT, defined as a reproducible arrhythmia of 4 or more
ventricular ectopic beats at any given setting of S2/S3/S4) (figure
4.8). Conversely, dogs which fail to produce S-VT or NS-VT in
response to stimulation (but which exhibit some ectopic response
during the stimulation protocol) are termed 'non-inducible'.
93
Inducible dogs were included in studies designed for the
evaluation of antiarrhythmic agents (chapters 6-8), while
non-inducible dogs were utilised in the evaluation of potential
proarrhvthmic agents (chapter 9). Dogs which failed to exhibit any
ectopic response during the stimulation protocol were returned to
the operating theatre for further coronary artery ligation.
In antiarrhythmic studies, drugs were administered at 5 min
intervals until the arrhythmia was abolished, side effects were
apparent or the dog died (ventricular fibrillation (VF) in response to
stimulation). Dogs with NS-VT were rechallenged every 5 min with
the stimulus setting which had produced the arrhythmia .If
stimulation failed to produce an arrhythmia after drug
administration, the protocol was continued as described above. Only
if this failed to produce the required ectopic response was the
arrhythmia considered abolished and the dog deemed non-inducible.
If a dog with S-VT reverted to sinus rhythm after administration,
the protocol was continued as above. Any dog still in S-VT at the end
of the experiment was returned to sinus rhythm with a short burst
of overdrive pacing.
In proarrhythmic studies dogs were rechallenged 5 min after
each dose of drug with the stimulus setting which had produced the
maximal ectopic response and this setting remained constant
whether or not arrhythmias were subsequently induced. After the
final dose of drug/placebo, the pacing protocol was repeated in full.
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4.2.3 Electrophysiological Studies
All chronic dogs included in either antiarrhythmic or
proarrhythmic drug studies with programmed electrical stimulation
also had PR intervals and QRS durations measured to the nearest 5
msec (paper speed 10 cm/sec) before and after each treatment. QT
intervals were similarly recorded and QTC was calculated using the
formula QTc=QTA/rr (Bazett,1920).
The effective refractory period (ERP) was taken as the
shortest inter-stimulus interval (to the nearest 5 msec) which
produced a ventricular response. Functional refractory period (FRP)
was estimated from the shortest inter-response interval measured
during the pacing protocol.
4.2.4 Staining of Necrotic Myocardium
All chronic dogs which died (or were destroyed) after the
immediate peri-operative period had the heart removed and infarct
mass determined using the method first described by Lie et al
(1975).This method is based on the observation that ischaemic or
infarcted myocardial cells can be distinguished from viable cells by
the former's ability to reduce particular dyes to produce coloured
precipitates. These dyes (in this case Triphenyl Tetrazolium
Chloride, or TTC) form precipitates in the presence of intact
dehydrogenase systems; necrotic areas lack such enzymatic activity
and will therefore fail to stain.
The solution used in our experiments was a 1% solution of TTC
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in a disodium hydrogen phosphate buffer. Since this is a light-
sensitive reagent, it was made freshly when required and kept in a
darkened flask.
The heart, once extracted, had all fatty tissue removed and the
aortic and pulmonary roots trimmed back, before being dried and
weighed (total mass). The atria were removed by cutting along the
A-V grooves and the ventricles stuffed with dry tissue paper to
maintain their shape. The ventricles were then placed at -20° C for
1-2 hours to firm the tissue sufficiently for accurate slicing. This
was performed using a bacon slicer with the ventricular mass
sectioned (10mm thickness) parallel to the A-V groove.The slices
were then immersed in the TTC solution and covered with a layer of
paper towel (to avoid air bubbles). Incubation proceded at 37°C for
15-20 min before the slices were rinsed in 0.9% saline and visually
inspected. By this stage normal myocardium should be expected to
have turned bright red and infarcted areas pale grey (figure 4.9).
After incubation, the free right ventricular wall was removed
to permit calculation of left ventricular mass; the infarct
(unstained tissue) was then excised and its mass expressed as a
percentage of left ventricular mass.
4.3 Statistical Methods
In the ouabain-induced arrhythmia and the arrhythmia
occurring 24 hours after coronary artery ligation (chapter 5), the
number of ventricular ectopic beats was expressed as a fraction of
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the total number of beats for two 5 min periods prior to the
administration of drug. Thereafter the same parameters were
counted (ventricular ectopic beats : total number of beats) for each
5 min period for the duration of the experiments. Means, standards
deviations and standard errors were calculated for each group at
each dose of drug, and comparisons made with the second control
period (-5 min to time zero) using Student's t-tests.
With the two adrenaline-induced arrhythmias (the halothane-
sensitized model and the model 3-5 days after coronary artery
ligation: chapter 5), the number of ventricular ectopic beats was
measured for each 5 min period following the administration of
adrenaline. Means, standard deviations and standard errors were
calculated for each group at each dose of drug, and comparisons
made with the values for the second test dose for each group using
Student's t-tests.
For the arrhythmias of acute coronary ischaemia (chapter 6),
standard errors for the data obtained were sufficiently large to
question a normal distribution. For this reason, the total number of
ventricular ectopic beats for each of the 2 drug groups was
compared with placebo using the non-parametric Mann-Whitney U
test.
Results of the effects of drugs on the arrhythmias produced by
programmed electrical stimulation were ranked (1,2,3) respectively
for abolition of arrhythmia, no change, or death (antiarrhythmic
studies, chapters 6-8) and compared with placebo using the non-
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parametric Mann Whitney U test. In the proarrhythmic study
(chapter 9) results of programmed electrical stimulation were
ranked (0,1) for no change or induction of arrhythmia/death and
compared with placebo using the Mann-Whitney U test.
In those experiments where blood pressures and heart rates
were recorded, Student's t-tests were employed to compare values
with pre-treatment values in the studies which did not employ
placebo groups. Where placebo groups were included, variations were
studied using one-way analysis of variance with the method of
contrasts used to compare each group with placebo.
Variations in electrophysiological parameters (chapters 6-9)
were analysed using Student's t-tests. Unless otherwise stipulated,
all analyses refer to comparisons with the corresponding
(pre-treatment or post-treatment) placebo value.
Inducibility of arrhythmias as a function of time after
coronary artery ligation (chapter 10) was evaluated using a
chi-squared contingency table analysis, the factors being time and
arrhythmia status. Significant differences were taken as indicating
a trend. Variations in infarct sizes as functions of both inducibility
and time after coronary artery ligation were studied by one-way
analysis of variance using multiple comparisons. The latter tests
offer significance at the 5% level only; otherwise all statistical
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Figure 2.
Examples of the adrenaline-induced arrhythmia in a dog respired with halothane. The
upper example shows a reproducible arrhythmia suitable for the testing of an
antiarrhythmic compound, while the lower example shows the successful termination of







Examples of the arrhythmias of acute coronary ischaemia. This
continuous ECG strip shows 2 periods of arrhythmic activity:
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Figure 5.
Example of the adrenaline-induced arrhythmia in a conscious dog,
3-5 days after experimental coronary artery ligation.
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Figure 6. Surgical preparation of the chrc r.ic canine model of myocardial infarction
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Examples of sustained (upper) and non-sustained (lower) ventricular
tachycardia in response to programmed electrical stimulation (PES) in
conscious dogs 7-30 days after experimental coronary artery ligation.





Staining of necrotic myocardium using Triphenyl Tetrazolium Chloride
(TTC). Normal myocardium (intact dehydrogenase systems) reduces the TTC
to a bright red precipitate while infarcted areas remain pale grey.
(Note ligature in lower picture and pacing electrode on upper).
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Chapter 5. EFFECTS OF THE MYOCARDIAL-SELECTIVE g-1
ADRENOCEPTOR ANTAGONIST UK-52046 AND ATENOLOL.




Following the introduction of the a and 3 adrenergic receptor
concept by Ahlquist (1948), it was generally believed that
myocardial adrenergic receptors were exclusively of the 3 type. It
was Govier (1967, 1968) who first proposed the existence of
myocardial a receptors, but despite their subsequent confirmation
both in animals (Rabinowitz et al, 1975; Wagner and Brodde, 1978)
and man (Schumann et al, 1978), investigation into the cardiac
effects of adrenergic stimulations have continued to concentrate
largely on the 3-adrenergic system. It has nevertheless been known
for some time that a adrenoceptor antagonists can prevent
catecholamine-induced ventricular arrhythmias (Leimdorfer, 1953).
More recently it has been shown that enhanced a adrenoceptor
responsiveness is a feature of myocardial ischaemia (Juhasz-Nagy
and Aviado, 1976; Sheridan et al, 1980) and that this is correlated
with an increase in a adrenoceptor concentration (Corr et al, 1981).
Furthermore, it has been suggested that the malignant arrhythmias
associated with myocardial ischaemia may be mediated primarily by
a adrenoceptors (Benfey, 1982; Sheridan and Culling, 1985).
The aim of this study was to evaluate the antiarrhythmic
effects of a myocardial-selective a1 adrenoceptor antagonist
UK-52046 (4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetra
hydroisoquinolin-2-yl) quinolin hydrochloride) and the 31 selective




Four models were used in this study:
(a) The ouabain-induced arrhythmia.
(b) The halothane-adrenaline arrhythmia.
(c) The arrhythmia 24 hours after coronary artery ligation.
(d) The adrenaline-induced arrhythmia 3-5 days after coronary
artery ligation.
For methodological details, please refer to chapter 4.
Drug used
Halothane (May and Baker); + adrenaline injection B.P. (Antigen
Ltd); ouabain octahydrate (Sigma Ltd); UK-52046
[4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoqu
inolin-2-yl) quinolin hydrochloride] was available as the methane
sulphonate, MW 490 (Pfizer Laboratories Ltd); atenolol (Stuart
Pharmaceuticals Ltd). Dose of UK-52046 and atenolol are expressed
in terms of the free base.
Statistics




Observations were made in 2 groups of 6 dogs in which the
intravenous administration of ouabain had produced a rapid
multifocal ventricular tachycardia. The required doses of ouabain
(65.8 + 7.4 (mean + SEM) pg/kg and 68.3 + 4.2 pg/kg for UK-52046
and atenolol groups respectively) were similar to those in a previous
study which established that this arrhythmia persists for more than
2 hours (Allen et al, 1971). After the arrhythmia had been
established for 10 min, drugs were given intravenously in increasing
doses at intervals of 5 min.
The administration of up to 64 pg/kg UK-52046 had no effect
upon the number of sinus beats in each 5 min period (figure 5.1).
mean systolic pressure fell from an initial 295.0 ±. 27.0 to 198.0 +.
31.3 mmHg after 2.0 pg/kg (P<0.05). After 32 pg/kg of UK-52046,
this had further fallen to 110.0 + 9.1 mmHg (P<0.01).
The effects of atenolol are summarised in figure 5.2. The
administration of up to 400 pg/kg of atenolol had no effect upon the
number of sinus beats in each 5 min period; after 800 pg/kg the
number of sinus beats fell (p<0.05). Mean systolic pressure fell from
an initial 220.0 + 14.8 to 193.3 + 18.7 after 12.5 pg/kg of atenolol
(p<0.05). After 800 pg/kg this had further fallen to 140.0 ± 25 mmHg
(p<0.01).
Halothane-adrenaline arrhythmias
Observations were made in 3 groups of 6 anaesthetised dogs.
The mean dose of adrenaline required to produce an arrhythmia in
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each group was 4.3 ±_ 0.7 pig/kg (UK-52046), 4.0 ±_ 0.9 pg/kg
(atenolol) and 7.6 + 0.7 pg/kg (combination).
In the UK-52046 group, the mean number of ectopic beats after
the test dose of adrenaline was 52.2 + 6.6 pg/kg. After 0.25 pg/kg
of drug this had fallen to 28.8 +. 7.7 (p<0.05). The arrhythmia was
prevented by a mean dose of 3.8 + 1.4 pg/kg of UK-52046 (figure
5.3).
The test dose of adrenaline produced a significant increase in
blood pressure before the onset of arrhythmia, with the peak blood
pressure response occurring shortly after the start of arrhythmia.
With doses of UK-52046 which prevented the arrhythmia, this
pressor response to adrenaline was significantly reduced (table 5.1);
Initial blood pressure (before the administration of adrenaline) was
also reduced compared with control values (169.2 + 28.1 and 216.7 +
29.2 mmHg respectively) but the difference did not reach statistical
significance. No change in heart rate was observed as the result of
UK-52046 in doses of up to 8 pg/kg (figure 5.3).
In the atenolol group the mean number of ectopic beats after
the test dose of adrenaline was 32.0 + 5.2. This had fallen (p<0.01)
after 6.25 pg/kg of drug and the arrhythmia was prevented by a
mean dose of 14.6 +. 2.1 pg/kg of atenolol (figure 5.4). Doses of
atenolol which prevented the arrhythmia were associated with a fall
in blood pressure, but this was not significant and the pressor
response to adrenaline was maintained (table 5.1). Atenolol at doses
of 12.5 pg/kg and 25 pg/kg produced significant reductions in heart
1 12
rate compared with placebo (147.0 + 4.1, 142.0 and 168.8 + 7.5 per
min respectively), but the adrenaline-induced increase in heart rate
seen in the control arrhythmia was maintained in the protected
arrhythmia (table 5.1).
In the group which were given a combination containing equal
amounts of UK-52046 and atenolol the mean number of ectopic beats
in the control arrhythmia was 97.8 + 17.1. This had fallen (p<0.05)
after 0.25 jig/kg of each drug and was prevented after a mean dose
of 0.36 + 0.1 jag/kg of each (figure 5.5). The pressor response to
adrenaline was maintained at doses which prevented the arrhythmia.
The combination in doses of up to 1 jig/kg of each drug had no effect
on heart rate but the adrenaline-induced increase in heart rate was
attenuated in the protected arrhythmias (table 5.1).
Arrhythmias 24 hours after coronary artery ligation
Observations were made in 2 groups of 6 conscious dogs,
22-24 hours after experimental coronary artery ligation. The number
of sinus beats varied among dogs during the control period but was
never greater than 20%.
The effects of UK-52046 are summarised in figure 5.6. After
16 p.g/kg and 32 p.g/kg of drug the number of sinus beats in each 5
min period had increased from a control value of 137.7 + 47 p.g/kg to
586 ±. 128.9 pig/kg and 662.3 + 99.1 jig/kg respectively (p<0.01).
These 2 doses of UK-52046 were also associated with a fall (p<0.05)
in the total ventricular rate. Blood pressure fell (p<0.05) with doses
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BEFORE AT PEAK AT ONSET OF
ADRENALINE RESPONSE ARRHYTHMIA
DRUG MEAN SYSTOLIC PRESSURE (mmHg)
CONTROL ARRHYTHMIA
UK-52046 216.7 ±29.2 "304.2 + 34.9 "242.5 ± 30.2
Atenolol 211.7 ±21.1 "288.3 ±19.1 "255.8 ± 16.0
Combination 145.8 ± 18.0 "318.3 ±24.1 "235.8 ± 29.4
PROTECTED ARRHYTHMIA
UK-52046 169.2 ±28.1 177.5 ±27.4
Atenolol 157.5 ± 14.2 "200.0 ±12.9
Combination 135.0 + 18.4 "245.0 + 14.3
HEART RATE (beats/min)
CONTROL ARRHYTHMIA
UK-52046 171.0 ± 9.2 178.7 ±4.2 187.3 ± 6.4
Atenolol 168.8 ± 7.5 *183.0 ± 8.2 *183.0 ± 7.2
Combination 153.3 ± 6.8 *199.0 ± 5.5 *191.7 ± 5.2
PROTECTED ARRHYTHMIA
UK-52046 168.3 ±10.0 172.0 ±6.7
Atenolol 145.0 ± 3.9 *154.0 ± 3.7
Combination 150.3 ±10.8 173.0 ± 8.4
Table 5.1
Arterial pressure and heart rate (mean ± SEM) during the halothane-adrenaline arrhythmia
recorded before the test dose of adrenaline, at peak response and at the onset of the arrhythmia.
Values are given for responses before the various treatments (control arrhythmia) and after
preventative doses of the respective therapies (protected arrhythmia).
*p<0.05 **p<0.01 (compared with values before adrenaline).
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of 8 pg/kg and above.
Atenolol in doses of up to 800 pg/kg had no effect upon the
same arrhythmia in a second group of 6 conscious dogs (figure 5.7).
Blood pressure did not vary during the course of the experiment.
Adrenaline-induced arrhythmia 3-5 davs after coronary artery
ligation
Observations were made in 3 groups of 6 conscious dogs. The
dogs were studied 72 hours after coronary artery ligation but only
included if an initial 15 min ECG recording showed no evidence of
arrhythmia. If any ectopics were observed the experiment was
delayed a further 24 hours. Any dog not in sinus rhythm at 120 hours
was excluded from the study. The mean dose of adrenaline required
to produce an arrhythmia in each group was 15.0 ±_ 2.2 pg/kg
(UK-52046), 15.0 + 2.2 pg/kg (atenolol) and 18.3 + 4.0 pg/kg
(combination).
In the UK-52046 group the mean number of ectopic beats after
the test dose of adrenaline was 265.7 ± 33.4 pg/kg; a significant
reduction was apparent after 0.25 pg/kg of UK-52046 ( 128.0 + 24.5
pg/kg, p<0.01) and the arrhythmia was prevented in 6/6 dogs with a
mean dose of 3.7 + 1.4 pg/kg (figure 5.8). There was no significant
change in blood pressure although the pressor response to adrenaline
was reduced from 153.7 + 26.5 mmHg in the control arrhythmia to
58.7 ± 4.3 mmHg in the protected state (p<0.05). Compared with the
control period, heart rate increased (p<0.01) after 1 pg/kg of drug
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(117.7 +. 10.4 and 138.3 + 10.6 beats per min respectively). After 8
pg/kg this had further increased to 157.0 + 7.0 per min.
The results for the atenolol group are summarised in figure
5.9. The mean number of ectopic beats after adrenaline was 277.5 +
91.2; after 100 pg/kg atenolol this had fallen to 31.1 ±_ 17.2
representing an 84.4% reduction (p<0.01). Further increases in the
dose of atenolol were not possible because of increasing agitation in
the dogs. There was no change in blood pressure, and the pressor
response to adrenaline although attenuated compared with control
values, was still highly significant (140 + 11.9 mmHg and 173 + 13.5
mmHg respectively).
In the group studied with a combination of UK-52046 and
atenolol, the mean number of ectopic beats after adrenaline was
140.5 + 31.5. The arrhythmia was prevented in 6/6 dogs after a mean
dose of 3.7 + 1.1 pg/kg of each drug. With the arrhythmia protected
the pressor response to adrenaline was not significantly reduced and
overall blood pressure did not change. However, as with the
UK-52046 group, heart rate increased (p<0.01) after 2 pg/kg
reaching a maximum of 146.3 + 6.8 beats/min after the final dose






Effects of the intravenous administration of UK-52046 on the
ouabain-induced arrhythmia in a group of 6 anaesthetized dogs
The histograms show the ventricular rate (clear columns) and
number of sinus beats (shaded) for each 5 min period. Values
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Figure 2.
Effects of the intravenous administration of atenolol on the
ouabain-induced arrhythmia in a group of 6 anaesthetized dogs.
The histograms show the ventricular rate (clear columns) and
number of sinus beats (shaded) for each 5 min period. Values

















Effects of the intravenous administration of UK-52046 on the
halothane-adrenaline arrhythmia in a group of 6 anaesthetized
dogs. Dose of adrenaline required to produce the arrhythmia
























Effects of the intravenous administration of atenolol on the
halothane-adrenaline arrhythmia in a group of 6 anaesthetized
dogs. Dose of adrenaline required to produce the arrhythmia
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Figure 5.
Effects of the intravenous administration of a combination
containing equal parts of UK-52046 and atenolol on the
halothane-adrenaline arrhythmia in a group of 6 anaesthetized
dogs. Dose of adrenaline required to produce the arrhythmia
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Figure 6.
Effects of the intravenous administration of UK-52046 upon
the ventricular arrhythmia occurring 24 hours after
experimental coronary artery ligation. The histograms show the
ventricular rate (clear columns) and number of sinus beats
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Figure 7.
Effects of the intravenous administration of atenolol upon the
ventricular arrhythmia occurring 24 hours after experimental
coronary artery ligation. The histograms show the ventricular
rate (clear columns) and number of sinus beats (shaded) for




















Effects of the intravenous administration of UK-52046 upon
the adrenaline-induced arrhythmia in a group of 6 conscious
dogs, 3-5 days after experimental coronary artery ligation.
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Figure 9.
Effects of the intravenous administration of atenolol upon the
adrenaline-induced arrhythmia in a group of 6 conscious dogs,
3-5 days after experimental coronary artery ligation. Dose of
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control 0.0625 0-25 1.0 4.0
UK-52046 + ATENO LO L
(ug/kg of each)
* p<0.05
** p < 0.0 1
Figure 10.
Effects of the intravenous administration of a combination
containing equal parts of UK52046 and atenolol upon the
adrenaline-induced arrhythmia in a group of 6 conscious dogs,
3-5 days after experimental coronary artery ligation. Dose of
adrenaline required to produce the arrhythmia was 7.6±0.7
ug/kg (mean±SEM).
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Chapter 6. EFFECTS OF THE MYOCARDIAL-SELECTIVE




Following the beneficial reports of UK-52046 as an
antiarrythmic agent in various experimental models where
arrhythmia production is dependent upon enhanced automaticity
(chapter 5) it was decided to extend studies with the drug to include
two models which depend upon reentrant mechanisms for arrhythmia
genesis.
Methods
The models used in this study included the arrhythmias of
acute coronary ischaemia and the arrhythmias produced by
programmed electrical stimulation in a chronic canine model of
myocardial infarction. The latter model also included the
measurement of electrocardiographic parameters and refractoriness.
For methodological details, please refer to chapter 4.
Drugs Used
UK-52046 (4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,
4-tetrahydroisoquinolin-2-yl) Quinolin hydrochloride). The drug was
available as the methane sulphonate, molecular weight 490 (Pfizer
Laborotories Ltd). All doses are expressed in terms of the free base.
Statistics
Details covered in chapter 4.
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Results
Arrhythmias following acute myocardial ischaemia
A total of 24 dogs were studied. The median number of
ventricular ectopic beats in the 12 dogs which received placebo was
190 (range 4-674), with peaks at 5-10 min and 20-25 min (values
given as mean ± SEM in figure 6.1, table 6.1). The corresponding value
for the group which received UK-52046, 4 jig/kg was 246 (9-1204),
again with a biphasic distribution (table 6.1); In the group which
received UK-52046, 8 pig/kg, the number of ectopic beats was
significantly reduced with a median of 12 (range 1-154).
Mean initial systolic blood pressures for the 3 groups were
respectively 75.9 +. 8.3 mmHg (placebo), 74.2 ±_ 12.2 mmHg
(UK-52046, 4 jig/kg) and 80.8 + 6.7 mmHg (UK-52046, 8 jig/kg)
(differences not statistically significant). However, both 4 pig/kg
and 8 p.g/kg of drug produced significant falls in systolic pressure
which persisted throughout the duration of the experiments (table
6.1).
Programmed Electrical Stimulation
Two groups of six inducible dogs were randomly allocated to
receive increasing intravenous doses of UK-52046 or placebo.
For the 6 dogs in the placebo group, programmed stimulation
resulted in a reproducible NS-VT in 5 dogs and a sustained VT in one
dog prior to treatment. Of the 5 dogs with NS-VT, 3 remained
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inducible when stimulated after each of 7 doses of placebo; the
other 2 developed VF when stimulated 5 min after the first dose of
placebo. The dog with S-VT remained in this arrhythmia throughout
the duration of the experiment (figure 6.2).
The effects of UK-52046 on the arrhythmias produced by PES
are illustrated in figure 6.3. In this group 5/6 dogs had a NS-VT and
one was in S-VT prior to treatment. Of the 5 with NS-VT, 2 became
non-inducible after 4.0 pg/kg of drug, one remained unchanged and 2
died when stimulated after 8 jig/kg and 64 pg/kg respectively. The
dog with S-VT remained in this arrhythmia throughout the duration
of the experiment. UK-52046 was well tolerated up to doses of 64
pg/kg. Statistical analysis indicated that, when compared with
placebo, UK-52046 did not exhibit significant antiarrhythmic
activity.
Blood Pressure and Heart Rate
In the placebo group mean initial systolic pressure for the 6
dogs was 155 + 6.9 (mean ± SEM) mmHg. The corresponding heart rate
was 114.2 + 12.0 per min. Neither value altered significantly during
the experiment (figure 6.2).
Mean intial systolic pressure for the group receiving
UK-52046 was 171 + 5.6 mmHg. After 4 pg/kg this had fallen to 136
+ 13.6 mmHg (p<0.05 compared with placebo); further falls were
apparent with increasing doses of drug (figure 6.3). Heart rate rose
from an initial 95.8 + 7.5 per min to 116.7 + 5.9 per min (difference
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not statistically significant). Pre-treatment figures for the placebo
group were not statistically different from the corresponding values
for the 6 dogs receiving UK-52046, nor was any change observed as a
result of drug therapy (table 6.2). pre-treatment figures for the
placebo group were not statistically different from the
corresponding values for the 6 dogs receiving UK-52046, nor was
any change observed as a result of drug therapy (table 6.2).
Electrophysiological Measurements
The effects of placebo and UK-52046 upon the PR interval,
QRS duration, QTC and refractory periods are summarised in table
6.2. Mean PR for the 6 dogs before placebo was 0.11 sec; after
placebo this had increased to 0.115 sec, but the difference was not
statistically significant. Similarly, no charge occured in mean QRS
(0.08-0.085), mean QTC (0.30-0.31 sec), mean ERP (0.105-0.11 sec)
and mean FRP (0.165-0.17 sec) before and after placebo
respectively. The pre-treatment figures for the placebo group were
not statistically different from the corresponding values for the 6
dogs receiving UK-52046, nor was any charge observed as the result
of drug therapy (table 6.2)
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NUMBER OF ECTOPIC BEATS
Time following coronary artery ligation (min)
DRUG n '0-5 5-10 10-15 15-20 20-25 25-30 total no
PLACEBO 12 14.7 47.2 12.1 25.7 101.2 56.2 190
+8.8 +31.5 +8.3 +18.8 +37.7 +13.9 (4-674)
UK-52046 6 3.1 41.3 5.5 1.8 244.6 123.2 246
4 |ig/kg +1.9 +38.9 +5.1 +1.8 +131.2 +59.8 (9-1204)
UK-52046 6 5.8 6.3 7.6 9.6 7.5 4.8 12
8 (ig/kg ±5.8 +5.2 +5.7 +7.2 +6.3 +3.0 (1-154)
SYSTOLIC BLOOD PRESSURE
DRUG n Before drug 0
Time following coronary artery ligation (min)
5 10 15 20 25 30
PLACEBO 12 75.9 82.1 90.0 91.7 90.4 91.8 90.0 88.8
+8.3 +7.7 +7.9 +6.6 +6.2 +5.4 +4.9 +4.9
UK-52046 6 74.2 65.8 64.2* 65.0* 67.5* 65.8'






+ 6.8 +7.5 ±6.7
50.0** 57.5** 58.5* 65.0* 64.0*
±5.0 ±12.7 ±12.1 ±10.7 ±10.4
Table 6.1
Number of ventricular ectopic beats (upper) and mean systolic blood pressures (lower) in response to
acute coronary ischaemia in 3 groups of anaesthetized dogs. Coronary artery ligation was performed
5 min after administration of placebo (n=12), UK-52046 4pg/kg (n=6) or UK-52046 8pg/kg (n=6)
*p<0.05 **p<0.01 (compared with placebo).
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Placebo
Parameter Before Drug After Drug
QTC 0.30 + 0.01 0.31 + 0.02
QRS 0.08 ± 0.005 0.085 + 0.005
PR 0.011 ± 0.005 0.115 ± 0.005
ERP 0.105 + 0.005 0.11 + 0.005
FRP 0.105 ± 0.005 0.11 + 0.01
UK-52046
Parameter Before Drug After Drug
QTC 0.26 ± 0.02 0.295 ± 0.01
QRS 0.07 + 0.005 0.075 + 0.005
PR 0.011 ± 0.005 0.10 + 0.005
ERP 0.125 ± 0.005 0.12 + 0.005
FRP 0.18 + 0.005 0.175 + 0.01
Table 6.2
Effects of placebo and UK-52046 on the corrected QT internal (QTC) ,
QRS duration (QRS), PR interval (PR) and effective (ERP) and
functional (FRP) refractory periods in 2 groups of 6 dogs.




















Mean number of ventricular ectopic beats occurring in each 5
min period following the production of a critical stenosis of
the left anterior descending coronary artery in 12
anaesthetized greyhounds. The histogram shows the
characteristic biphasic distribution with peaks at 5-10 min
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Figure 2.
Effect of placebo (doses 1,2,3 etc) upon the arrhythmias
produced by programmed electrical stimulation in 6 conscious
dogs, 7-30 days after experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia














** p <0.0 1
drug 1.0 2.0 4.0 8.0 16.0 32.0 64.0





Effect of increasing doses of UK-52046 upon the arrhythmias
produced by programmed electrical stimulation in 6 conscious
dogs, 7-30 days after experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia
S-VT, Sustained Ventricular Tachycardia
VF, Ventricular Fibrillation
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Chapter 7. A COMPARISON OF THE EFFECTS OF ATENOLOL
AND MEXILETINE ON EXPERIMENTAL ARRHYTHMIAS
PRODUCED BY PROGRAMMED ELECTRICAL STIMULATION
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Introduction
Reference has already been made to the studies with
various class 1 antiarrhythmic drugs which showed that, whilst
these agents were capable of suppressing the acute and chronic
ventricular arrhythmias associated with myocardial infarction, none
demonstrated any associated reduction in mortality. In the same
chapter (chapter 2.4), attention was drawn to the trials which
provided good evidence that the use of |3-adrenergic receptors in the
post-infarction period was associated with a reduction in both
reinfarction and sudden death. The purpose of this study was to
evaluate the antiarrhythmic properties of mexiletine, a commonly
used class 1 antiarrhythmic agent, and atenolol, a [3-adrenergic
receptor antagonist, in experimental arrhythmias produced by
programmed electrical stimulation. By so doing, it was intended to
see whether the clinical findings described above could be
reproduced in this particular model, and if so, if they could be
attributed to any electrophysiological characteristics of the drugs
under study.
Methods
The surgical procedures, stimulation protocol and
measurement of electrophysiological variables are similar to those
employed for the study described in chapter 6. Methodological
details are given in chapter 4. Since a number of studies with
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programmed electrical stimulation were carried out simultaneously,
one control group serves for the comparison of all drug data in
antiarrhythmic studies with inducible dogs.
Drugs Used
Mexiletine hydrochloride (Boehringer Ingelheim Laboratories)
Atenolol hydrochloride (Stuart Pharmaceuticals)
Drugs were freshly prepared by dissolution in 0.9%saline. All
doses expressed are in terms of the hydrochloride.
Statistics
Details covered in chapter 4.
Results
The study comprises a total of 18 dogs. Three groups of six
inducible dogs were randomly allocated to receive increasing
intravenous doses of atenolol, mexiletine or placebo.
For the 6 dogs in the placebo group, programmed
stimulation resulted in a reproducible NS-VT in 5 dogs and a S-VT in
one prior to treatment. Of the 5 dogs with NS-VT, 3 remained
inducible when stimulated after each of 7 doses of placebo; the
other 2 developed VF when stimulated 5 min after the first dose of
placebo. The dog with S-VT remained in this arrhythmia throughout
the duration of the experiment (figure 6.2).
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Of the 6 dogs administered atenolol (figure 7.1), 5 had a
reproducible NS-VT while one was in a S-VT prior to treatment. Of
the 5 with NS-VT, 3 became non-inducible after doses of 8 ug/kg, 64
ug/kg and 128 ug/kg respectively, one was still inducible after 256
ug/kg and one died when stimulated after 1 ug/kg. The dog with
S-VT became non-inducible after 256 ug/kg. No adverse effects
were apparent at the doses used.
In the mexiletine group all 6 dogs had a reproducible NS-VT
at the start of the experiment. Of these, 5 remained inducible after
doses of up to 16 mg/kg and one dog died when stimulated after 4
mg/kg (figure 7.2). All the dogs which received 16 mg/kg exhibited
generalised rigidity which prevented continuation of the experiment.
Statistical analysis revealed that atenolol was
significantly (p<0.05) better than placebo in abolishing arrhythmias
produced by programmed electrical stimulation and protecting
against VF. The difference between mexiletine and placebo was not
statistically significant.
Blood Pressure and Heart Rate
In the placebo group mean initial systolic pressure for the
6 dogs was 155 ± 6.9 (mean ± SEM) mmHg. The corresponding heart
rate was 114.2 ± 12.0 per min. Neither value altered significantly
during the experiment (figure 6.2).
Mean intial systolic pressure for the group receiving
atenolol was 162 ± 9.0 mmHg; after 256 ug/kg of drug this had
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fallen to 147.5 ± 27.4 mmHg but the drop was not significant (figure
7.1). Heart rate, however, fell from an initial 110.4 ± 7.3 per min to
90.4 ± 6.5 per min (p<0.05 compared with placebo).
Mean initial systolic pressure for the mexiletine group was
165.5 ± 10.7 mmHg and did not vary significantly during the course
of the experiment. Mean initial heart rate in this group was 119.0 ±
12.5 per min; this did not vary significantly with doses of up to 8
mg/kg of mexiletine but after 16 mg/kg increased to 176.5 ± 11.5
per min (p<0.05 compared with placebo).
Electrophysiological Measurements
The effects of placebo upon the PR interval, QRS duration,
QTC and refractory periods are summarised in table 6.2. The
pre-treatment figures for placebo were not significantly different
from the corresponding values for either drug group (table 7.1).
There was no significant change in any parameter as the result of
treatment with mexiletine (table 7.1), but atenolol resulted in a
significant (p<0.05) prolongation of the ERP (0.115 ± 0.005 sec
before treatment to 0.13 ± 0.005 sec after drug). FRP was also noted




Parameter Before Drug After Drug
QTC 0.31 ± 0.015 0.29 ± 0.005
CR3 0.08 ± 0.005 0.075 ± 0.005
PR 0.115 ± 0.005 0.12 ±0.01
ERP 0.115 ± 0.005 0.13* ±0.005
FRP 0.175 ± 0.005 0.185 ±0.01
Mexiletine




ERP 0.1 15 ±
FRP 0.16 ±
0.005 0.305 ± 0.01
0.005 0.075 ± 0.005
0.005 0.105 ± 0.005
0.005 0.115 + 0.005
0.005 0.165 ± 0.005
Table 7.1
Effects of atenolol and mexiletine on the corrected QT interval (QTC), QRS
duration (QRS), PR interval (PR) and effective (ERP) and functional
(FRP) refractory periods in 2 groups of 6 dogs. Results are expressed in
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Effect of atenolol upon the arrhythmias produced by
programmed electrical stimulation in 6 conscious dogs, 7-30
days after experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia
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Effect of mexiletine upon the arrhythmias produced by
programmed electrical stimulation in 6 conscious dogs, 7-30
days after experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia
S-VT, Sustained Ventricular Tachycardia
> VF, Ventricular Fibrillation
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Chapter 8. EFFECTS OF THE ENANTIOMERS OF TOCAINIDE
AND MEXILETINE ON EXPERIMENTAL ARRHYTHMIAS
PRODUCED BY PROGRAMMED ELECTRICAL STIMULATION
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Introduction
Tocainide (2-amino-2',6'-propionoxylidide HCI) is a class 1b
antiarrhythmic agent, structurally related to lignocaine but with
high bioavailability and a long duration of action after oral
administration. The main indication for its use in man is in the
treatment of intractable ventricular arrhythmias (Zipes and Troup,
1978). The drug is used clinically as a racemic mixture, but it has
been shown that the R (-) enantiomer is up to three times as potent
as the S (+) enantiomer in protecting against chloroform-induced
fibrillation in mice (Byrnes et al, 1979). Similar, but less marked
differences in enantiomeric potency were also seen in the
arrhythmia occurring 24 hours after coronary artery ligation in dogs.
Additional studies have suggested differences in the metabolism
and/or excretion of the 2 enantiomers, resulting in lower plasma
concentrations of the R enantiomer both in animal (Gal et al, 1982)
and clinical (Sedman et al, 1984) studies
The purpose of this study was to investigate the
antiarrhythmic and electrophysiological effects of the racemic
mixture of tocainide and its enantiomers on experimental
arrhythmias produced by programmed electrical stimulation. During
the course of these experiments, we were fortunate enough also to
acquire a limited supply of the enantiomers of mexiletine, and so it
was decided to extend the study to include an analysis of the




The surgical procedures, stimulation protocol and
measurement of electrophysiological variables are similar to those
employed for the studies described in chapters 6 and 7. Measurement
of blood pressure in the conscious dog was not included in the




R (-) tocainide S (+) tocainide
R (-) mexiletine S (+) mexiletine
Tocainide and its enantiomers were provided by Hassle
laboratories (a subsidiary of AB Astra), Sweden. The enantiomers
were prepared (99.6% purity) by fractional crystallization of the
parent compound using di-p-toluyl-d and di-p-toluyl-l tartaric acid
(Byrnes et al, 1979). Solutions of each drug were freshly prepared by
dissolution of the hydrochloride powder in 0.9% saline. The




Details covered in chapter 4.
Results
The first part of the study comprised three groups of six
inducible dogs which were randomly allocated to receive increasing
(0.5, 1.0, 2.0 etc. mg/kg) intravenous doses of SR tocainide, S
tocainide, or R tocainide .
In the group which received racemic tocainide, 4/6 had an
initial NS-VT and 2/6 were in S-VT (figure 8.1). Of the 4 with
NS-VT, one became non-inducible after 16.0 mg/kg of drug, one
developed S-VT when stimulated after 16.0 mg/kg of drug but
reverted to a NS-VT after 32.0 mg/kg and 2 died when stimulated
after 0.5 mg/kg and 4.0 mg/kg respectively. The 2 dogs with S-VT
became non-inducible after 16.0 mg/kg and 32.0 mg/kg respectively
(figure 8.1). The mean effective dose of SR tocainide for the 3 dogs
which became non-inducible in this group was 21.3 mg/kg (range
16-32 mg/kg).
In the group receiving S tocainide, 3/6 dogs had a NS-VT and
3/6 were in S-VT at the start of the experiment (figure 8.2). Of the
3 with NS-VT, 2 became non-inducible after 0.5 mg/kg and 4.0
mg/kg respectively and one still demonstrated a NS-VT when
stimulated after 32.0 mg/kg. Of the 3 with S-VT, 2 became
non-inducible after 8.0 and 16.0 mg/kg respectively and in the third
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the S-VT degenerated into VF after 32.0 mg/kg. The mean effective
dose of S tocainide for the 4 dogs which became non-inducible in
this group was 7.1 mg/kg (range 0.5-16.0 mg/kg).
In the group receiving R tocainide, 5/6 dogs had a NS-VT and
one was in S-VT at the start of the experiment (figure 8.2). Of the 5
with NS-VT, 4 became non-inducible after doses of 0.5 mg/kg, 0.5
mg/kg, 4.0 mg/kg and 32.0 mg/kg of drug. The dog with S-VT became
non-inducible after 8.0 mg/kg of drug. The mean effective dose of R
tocainide for the 5 dogs which became non-inducible in this group
was 9.0 mg/kg (range 0.5-32.0 mg/kg).
All the dogs which received 32.0 mg/kg of the racemic mixture
or enantiomers became tremulous and agitated with profuse
salivation. Two dogs developed generalised rigidity at this dose but
recovered completely within 30 minutes.
Statistical analysis indicated that the S and R enantiomers of
tocainide were significantly (p<0.05 and p<0.01 respectively) better
than placebo (chapters 6,7) in abolishing ventricular arrhythmias
produced by programmed stimulation and protecting against death.
The difference between the racemic mixture and placebo did not
reach statistical significance.
S and R mexiletine were studied in groups of 5 and 6 dogs
respectively (there being insufficient isomer to complete a sixth
study for the S group). All dogs had reproducible non-sustained
ventricular tachycardias at the start of the experiments. In the
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group receiving S mexiletine, one dog became non-inducible after 1.0
mg/kg of drug, 2 continued to demonstrate a NS-VT after doses of
8.0 mg/kg and 16.0 mg/kg respectively and one died when stimulated
after 8.0 mg/kg. The fifth dog developed a sustained VT when
stimulated after 16.0 mg/kg; the arrhythmia persisted for 5 min but
degenerated into VF during an attempt to pace back into sinus
rhythm (figure 8.4). In the group administered R mexiletine 3 dogs
became non-inducible (2 after 0.5 mg/kg, one after 8.0 mg/kg), one
continued to demonstrate a NS-VT after 16.0 mg/kg and 2 died when
stimulated after 1.0 mg/kg and 8.0 mg/kg (figure 8.4). The same
features of agitation which were apparent in the tocainide
experiments also prevented the continuation of these experiments
beyond 16.0 mg/kg of either enantiomer.
When subjected to statistical analysis, these results failed to
demonstrate any significant antiarrhythmic protection when either
enantiomer was compared with placebo. The same analysis, when
applied to racemic mexiletine, had also failed to demonstrate
antiarrhythmic efficacy (chapter 7).
Electrophysiological Measurements
The effects of placebo upon the PR interval, QRS duration, QTC
and refractory periods are summarised in table 6.2. The
pre-treatment figures for placebo were not different from the
corresponding values for tocainide or its enantiomers (table 8.1) or
either enantiomer of mexiletine (table 8.2). Similarly, there was no
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SR tocainide





















































































Effects of SR tocainide, S tocainide and R tocainide on the corrected QT
interval (QTC), QRS duration (QRS), PR interval (PR) and effective
(ERP) and functional (FRP) refractory periods in 3 groups of 6 dogs.
Results in seconds (mean ± SEM).
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S mexiletine
Parameter Before Drug After Drug
QTC 0.30 ± 0.015 0.285 ± 0.005
GRS 0.07 ± 0.005 0.07 ± 0.005
PR 0.11 ± 0.005 0.11 ± 0.005
ERP 0.115 ± 0.005 0.12 ± 0.005
FRP 0.165 ± 0.005 0.165 ±0.01
R mexiletine
Parameter Before Drug After Drug
QTC 0.305 ± 0.01 0.31 ± 0.015
GRS 0.08 ± 0.005 0.075 ± 0.005
PR 0.11 ± 0.005 0.105 ± 0.005
ERP 0.12 ± 0.005 0.125 ± 0.005
FRP 0.165 ± 0.005 0.17 ± 0.01
Table 8.2
Effects of S and R mexiletine on the corrected QT interval (QTC), QRS
duration (QRS), PR interval (PR) and effective (ERP) and functional
(FRP) refractory periods in 3 groups of 6 dogs.
Results in seconds (mean ± SEM).
significant change as the result of treatment with any of the drugs
under study (tables 8.1, 8.2).
The effective refractory period was defined as the shortest
coupling interval capable of producing conducted beats. The
functional refractory period was the minimum time between
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conducted beats (chapter 4.2.3). When the inter-response interval
was plotted against the inter-stimulus interval the graph displayed
a characteristic appearance (figure 8.3). The bottom of the 'hockey
stick' represents the slowing in conduction which occurs when
closely-coupled extrastimuli propagate at a time interval close to
the relative refractory period of the intervening tissue. In these
experiments FRP acted as an index of conduction within the
ventricular myocardium (Simson et al, 1979), and exhibited no
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Figure 1.
Effect of SR tocainide upon the arrhythmias produced by
programmed electrical stimulation in 6 conscious dogs, 7-30
days after experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia
S-VT, Sustained Ventricular Tachycardia
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Relationship between effective refractory period (ERP) and
functional refractory period (FRP) in a conscious dog during
programmed electrical stimulation. ERP was taken as the
shortest S1-S2 interval which produced a ventricular response.
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Effects of S and R mexiletine upon the arrhythmias
produced by programmed electrical stimulation.
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Histamine is a vasoactive amine found in mast cells
throughout the body. Although a physiological effect on the heart has
not been described, histamine is present in large quantities in
cardiac tissue (Vugman and Rocha e Silva, 1966) and has been shown
to increase sinus rate and contractility, prolong AV conduction and
enhance automaticity in an isolated preparation (Levi, 1972). Further
studies have characterized these effects into those mediated
respectively by H-| (prolonged conduction) and H2 (positive inotropic
and chronotropic effects and enhanced automaticity) receptors (Levi
et al, 1976). After the discovery that histamine levels were
significantly increased in patients after myocardial infarction (Rai
et al, 1976), it was suggested that histamine could induce
arrhythmias (Levi et al, 1981), especially under ischaemic
conditions (Cameron et al, 1983 (a)). Following the development of
the H2-specific antagonists in the late 1960's, Black and colleagues
showed that the characteristic cardiac effects of histamine in
isolated preparations could be selectively blocked by these drugs
(Black et al, 1972). The subsequent reports of sinus bradycardia
associated with cimetidine (Reding et al, 1977; Bournerias et al,
1978; Stimmesse et al, 1978; Karch and Becker, 1980; Matthews et
al, 1982) and ranitidine (Camarri et al, 1982; Shah, 1982) could
therefore be explained from a knowledge of the drugs'
pharmacological actions in blocking cardiac H2 receptors. Whilst
some have considered these effects antiarrhythmic (Ligumsky et al,
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1978; Cameron et al, 1983 (b)), there have been several reports
linking the intravenous use of H2 receptor antagonists with serious
cardiac arrhythmias (Cohen et al, 1979; MacMahon et al, 1981; King,
1981; Lineberger et al, 1985) and even sudden death (Shaw et al,
1980). The purpose of the present study was to investigate the
proarrhythmic and electrophysiological effects of cimetidine and
ranitidine in the chronic canine model of myocardial infarction
which has already been described for the investigation of
antiarrhythmic effects (chapters 6-8). Furthermore, in order to
validate the model's suitability for proarrhythmic studies, we
concurrently investigated the effects of quinidine, a class 1
antiarrhythmic agent with known proarrhythmic properties (Selzer
and Wray, 1964; Reynolds and Vander Ark, 1976; Jenzer and
Hagemeijer, 1976; Goldstein et al, 1984).
Methods
The surgical procedures, stimulation protocol and
measurement of electrophysiological variables are similar to those
employed for the study described in chapters 6-8, with the
exception that this study involved the use of dogs which were
non-inducible when challenged with programmed stimulation.
Methodological details are given in chapter 4.
Drugs Used
Quinidine sulphate (Sigma Chemical Company)
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Cimetidine base (Smith, Klein and French Laboratories)
Ranitidine hydrochloride (Glaxo Laboratories)
Each drug was available in powder form and was freshly
prepared by dissolution in 0.9% saline at room temperature.
Statistics
Details covered in chapter 4.
Results
The study comprised four groups of 6 dogs in which
reproducible ventricular tachycardias had previously been induced
but which were non-inducible on this occasion. The dogs were
randomly allocated to receive increasing (0.5, 1.0, 2.0 etc mg/kg)
intravenous doses of quinidine, cimetidine, ranitidine or placebo.
The effects of repeated stimulation in the 6 dogs in the
placebo group are illustrated in figure 9.1. Four dogs remained
non-inducible throughout the duration of the experiment, and dog
developed a reproducible NS-VT after the fourth dose of placebo and
was still inducible at the end of the experiment, and one dog
developed VF when stimulated 5 min after the first dose of placebo.
In the quinidine group, 3/6 dogs developed a NS-VT, one when
stimulated after 0.5 mg/kg and a further 2 when challenged after 4.0
mg/kg. Three dogs developed VF when stimulated after 4.0mg/kg, 8.0
mg/kg and 16.0 mg/kg respectively, (figure 9.2).
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In the cimetidine group (figure 9.3), 4/6 dogs remained
non-inducible when stimulated after doses up to 16.0 mg/kg (2 dogs)
and 32.0 mg/kg (2 dogs). One dog developed a reproducible NS-VT
when stimulated after 4.0mg/kg and was still inducible after 16.0
mg/kg. One dog developed VF when stimulated 5 min after 0.5 mg/kg
of cimetidine. Excess salivation and restlessness were noted in all
dogs which received 16.0 mg/kg, and necessitated abandoning the
experiment after this dose in 3 dogs (figure 9.3).
In the ranitidine group, three of the 6 dogs studied remained
non-inducible when stimulated after doses up to 4.0 mg/kg, 8.0
mg/kg and 16.0 mg/kg respectively (figure 9.4). Two dogs developed
a reproducible NS-VT after 0.5 mg/kg of ranitidine; of these, one
developed VF after 1.0 mg/kg and the other developed VF after 4.0
mg/kg. A third dog developed VF after 16.0 mg/kg of drug. Features
of salivation and restlessness were also apparent in this group,
requiring the experiment to be terminated after 4.0 mg/kg (one dog),
8.0 mg/kg (one dog) and 16.0 mg/kg (last remaining dog).
Statistical analysis indicated that there was a significant
(p<0.05) increase in arrhythmia induction and death when quinidine
was compared with placebo; no difference was observed when
cimetidine or ranitidine were similarly compared.
Blood Pressure and Heart Rate
In the placebo group, mean systolic pressure for the 6 dogs at
the start of the experiments was 170.0 ± 10.7 mmHg (mean ± SEM).
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The corresponding value for heart rate was 117.7 ± 6.4 per min.
There was no significant change in either value following 7 doses of
placebo (figure 9.1).
In the quinidine group, mean initial systolic pressure for the
six dogs was 150.0 ± 6.0 mmHg. After 1.0 mg/kg of drug this fell to
133.3 ± 6.0 mmHg (p<0.05 compared with placebo).Further falls were
apparent with increasing doses of drug (figure 9.2). Heart rate rose
from an initial 117.5 ± 12.2 per min to 155.2 ± 12.7 after 8.0 mg/kg
(p<0.05 compared with placebo).
Mean initial systolic pressure for the 6 dogs in the cimetidine
group was 153.3 ± 14.8 mmHg. After 32.0 mg/kg of drug this had
fallen to 135.0 ± 13.6 mmHg (figure 9.3), but the difference was not
statistically significant when compared with placebo. Heart rate
rose from an initial 111.8 + 9.6 per min to 164.4 ± 22.7 per min after
16.0 mg/kg (p<0.05) and 220.0 ± 14.7 after 32.0 mg/kg (p<0.01
compared with placebo).
Mean initial systolic pressure for the 6 dogs in the ranitidine
group was 166.7 ± 19.2 mmHg. After 16.0 mg/kg of drug this had
fallen to 145.0 mmHg, but the difference was not significant (figure
4). Mean heart rate rose from an initial 113.5 ± 7.5 per min to 150.3
± 9.6 per min after 8.0 mg/kg (p<0.05) and 180.0 ± 31.9 per min after
16.0 mg/kg (p<0.05 compared with placebo).
Electroohvsiological Measurements
The effects of placebo upon the PR interval, QRS duration, QTC
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and refractory periods are summarised in table 9.1. Mean PR for the
6 dogs before and after placebo was 0.11 sec and 0.105 sec
respectively (difference not statistically significant).
Similarly,there was no change in mean QRS (0.075 - 0.08 sec), mean
QTC (0.33 - 0.32 sec) or mean ERP (0.12 - 0.13 sec). FRP remained
constant at 0.175 sec. The pre-treatment values in the placebo group
(table 9.1) were similar to the pre-treatment values in each drug
group (table 9.2). There was no significant change in PR, QRS, or QTC
as the result of treatment with cimetidine or ranitidine but QTC
increased from 0.325 ± 0.01 sec to 0.355 ± 0.005 sec after quinidine
(p<0.01 compared with placebo). After both cimetidine and ranitidine
ERP and FRP appeared to shorten. This was more marked with
Placebo
Parameter Before Drug After Drug
QTc 0.33 ± 0.01 0.32 ± 0.01
QRS 0.075 ± 0.005 0.08 ± 0.005
PR 0.11 ± 0.005 0.105 ±0.005
ERP 0.12 ± 0.01 0.13 ± 0.005
FRP 0.175 ± 0.005 0.175 ± 0.005
Table 9.1
Effects of placebo on the corrected QT interval (QTC), QRS duration (QRS), PR
interval (PR) and effective (ERP) and functional (FRP) refractory periods in a
group of 6 non- inducible dogs. Results are expressed in seconds (mean ± SEM).
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Quinidine
Parameter Before Drug After Drug
QTc 0.325 ± 0.01 0.355*±0.005
GFB 0.07 ± 0.005 0.07 ± 0.005
PR 0.115 ± 0.005 0.115 ±0.005
ERP 0.125 ± 0.01 0.125 ± 0.005
FRP 0.165 ± 0.005 0.16 ± 0.005
Cimetidine
Parameter Before Drug After Drug
QTc 0.31 ± 0.01 0.33 ± 0.005
GRS 0.08 ± 0.005 0.07 ± 0.005
PR 0.105 ± 0.005 0.10 ± 0.01
ERP 0.13 ± 0.01 0.11 ± 0.01
FRP 0.17 ± 0.005 0.145 ±0.005
Ranitidine
Parameter Before Drug After Drug
QTC 0.315 ± 0.005 0.32 ± 0.01
CRS 0.08 ± 0.005 0.07 ± 0.005
PR 0.115 ± 0.005 0.115 ±0.005
ERP 0.135 ± 0.005 0.1 f
FRP 0.175 ± 0.005 0.13 - 0.135f
Table 9.2
Effects of quinidine, cimetidine and ranitidine on the corrected QT interval
(QTC), QRS duration (QRS), PR interval (PR) and effective (ERP) and
functional (FRP) refractory periods in 3 groups of 6 dogs. Results in seconds.
*p<0.05 (compared with placebo)
"fonly 3 results available
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ranitidine, with ERP and FRP decreasing from 0.135 - 0.1 sec and
0.175 - 0.135 sec respectively. However, in view of the small
numbers used (3 surviving programmed stimulation in the ranitidine
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Figure 1.
Effect of placebo upon the arrhythmias produced by programmed
electrical stimulation in 6 non-inducible dogs, 7-30 days after
experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia


















Effect of quinidine upon the arrhythmias produced by programmed
electrical stimulation in 6 non-inducible dogs, 7-30 days after
experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia
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Figure 3.
Effect of cimetidine upon the arrhythmias produced by programmed
electrical stimulation in 6 non-inducible dogs, 7-30 days after
experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia
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Figure 4.
Effect of ranitidine upon the arrhythmias produced by programmed
electrical stimulation in 6 non-inducible dogs, 7-30 days after
experimental coronary artery ligation.
NS-VT, Non-Sustained Ventricular Tachycardia




Chapter 10. INFARCT SIZES AND RELATIONSHIP TO




This chapter summarizes the results of infarct-size
determinations in all the dogs which were prepared for programmed
electrical stimulation during the tenure of the author's research
fellowship. The purpose of so doing was primarily to establish if
any relationship existed between the size of myocardial infarction
and inducibility of arrhythmias on challenge with stimulation; of
additional interest was to follow, with time, the macroscopic
evolution and regression of the infarct itself.
Methods
The staining methods for determination of infarct size are
described in chapter 4. The statistical analyses employed are
covered in the same chapter.
Results
A total of 119 dogs were studied. Of these, 87 (73.1%) were
alive and ambulant 24 hours after surgery. The remaining 32 (26.9%)
died from various causes, of which acute ischaemic ventricular
fibrillation was the most common, occurring in 20 (62.5%). Other
causes included irreversible bradycardia leading to asystole (3),
anaesthetic-related deaths (4), fatal haemorrhage (1) and
mechanical pump failure (1). One dog pulled its pacing wires out and
died from the resulting haemorrhage/tamponade and 2 animals
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appeared to recover from anaesthetic but were found dead the
following morning.
Of the 87 dogs which survived the immediate (24 hour) peri¬
operative period, 6 subsequently had to be destroyed, 3 on account
of severe wound infections, 2 for vomiting and dehydration
refractory to intravenous fluid replacement and one for severe
subcutaneous (surgical) emphysema at 48 hours. Fifteen dogs died
suddenly and unexpectedly during the first postoperative week: of
these, a ruptured left ventricle was diagnosed at post-mortem in
one but no cause was apparent in any of the remaining 11 which
were the subject of autopsy. It may be significant that in 2 of these
cases, death occurred when the dog was exercised outside on the
second postoperative day in particularly cold weather. Taken as a
group, these 'sudden, unexpected deaths' did not occur later than the
sixth postoperative day and had a mean infarct size of 11.1 ± 1.5%
of left ventricular (LV) mass.
Of the 87 dogs surviving surgery therefore, 66 (75.9%) reached
programmed electrical stimulation on the seventh postoperative day
(table 10.1). Of these 66, 25 died from ventricular fibrillation
during the pacing protocol before the administration of drug, 36
exhibited a non-fatal arrhythmia suitable for inclusion in an
antiarrhythmic drug study and 5 were deemed non-inducible by the
criteria defined in chapter 4. This is illustrated in table 10.1, a
flow diagram summarizing survival figures for all the dogs studied.
Infarct size estimations were available in 24 of the 25 dogs which
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died before drug administration and gave a mean value of 7.0 ± 1.8%
of LV mass.
The fate of the 41 dogs which were entered into drug studies
can be followed in table 10.1. Once a previously inducible animal
became non-inducible, it was entered into a proarrhythmic drug
study. If the animal survived and was found to be non-inducible
when next stimulated, it was either re-operated upon or destroyed.
It is interesting that, during the course of the work, 7 dogs were
inducible when stimulated a week after being non-inducible.
If the dogs which died prior to receiving drug are added to
those deemed inducible by the criteria established in chapter 4, and
the sum expressed as a percentage of the total number of dogs
stimulated, it can be seen that one week after surgery, 92.4% of the
dogs were inducible. At two weeks after surgery the corresponding
figure was 66.7%, with subsequent values of 64.3% and 55.6% for
the third and fourth postoperative weeks respectively. When
subjected to statistical analysis, these figures confirm a
significant reduction in inducibility with time. The results are
summarized in table 10.2, where rows 1 to 4 respectively refer to
the first, second, third and fourth stimulations.
Mean infarct size for all the dogs which died (pre- or
post-drug) at one week was 7.0 ± 0.5% of LV mass. The
corresponding values for those dogs which died at 2 and 3 weeks
were 5.8 ± 0.6% and 4.6 ± 0.8% respectively. Infarct size
determinations were available for only one of the 3 dogs which died
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in relation to stimulation at 4 weeks and in this case no infarct
could be visualised. Statistical analysis of these results confirms a
time-dependent decrease in infarct size which was of statistical
significance up to one week but did not alter significantly
thereafter (table 10.3).
Since dogs were not routinely destroyed for non-inducibility
per se, infarct sizes for the 'non-inducible group' were calculated
from those dogs which became inducible (and died) after inclusion
in a proarrhythmic study or which were destroyed for repeated
(successive occasions) non-inducibility. The resulting figure for
infarct size in this group was therefore 5.4 ± 1.6% of LV mass.
Statistical analysis failed to demonstrate a significant difference
between the inducible and non-inducible groups, although both were
significantly different from the 'sudden, unexpected death' group
(table 10.4).
Infarcts were predominantly subendocardial in nature, as
illustrated in figure 4.9. Occasionally large, transmural infarctions
were apparent; although this was the case with the dog which died
of a ruptured ventricle, no attempt was made to include this feature
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4 non-inducible, 2 inducible
Table 10.1.









Observed Frequency Table Percents of Column Totals
Column 1 Column 2 Totals:
Column 1 Column 2
Totals:
Row 1 61 5 66 Row 1 65.59% 21.74% 56.9%
Row 2 1 8 9 27 Row 2 19.35% 39.13% 23.28%
Row 3 9 5 1 4 Row 3 9.68% 21.74% 12.07%
Row 4 5 4 9 Row 4 5.38% 17.39% 7.76%








Column 1 Column 2 Totals:
Row 1 92.42% 7.58% 100% Row 1 52.91 13.09 66
Row 2 66.67% 33.33% 1 00% Row 2 21.65 5.35 27
Row 3 64.29% 35.71% 1 00% Row 3 11.22 2.78 1 4
Row 4 55.56% 44.44% 100% Row 4 7.22 1.78 9
Totals: 80.17% 19.83% 1 00% Totals: 93 23 116
Table 10.2
Analysis of the relationship between inducibility and time after coronary artery
ligation (key given in text)(Chi Square analysis).
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One Factor ANOVA X-|: Weeks Y-|: infarct sizes
Analysis of Variance Table
Source: DF: Sum Squares: Mean Square: F-test:
Between groups 3 247.227 82.409 7.99
Within groups 66 680.711 10.314 p= 1.0000E-4
Total 69 927.938
Model II estimate of between component variance = 24.032
One Factor ANOVA Xi: Weeks Yi: Infarct sizes
Group: Count: Mean: Std. Dev.: Std. Error:
Group 1 12 11.092 5.06 1.461
Group 2 39 7.015 2.878 .461
Group 3 13 5.823 2.296 .637
Group 4 6 4.617 2.056 .839
One Factor ANOVA Xi: Weeks Y-|: Infarct sizes
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t:
Group 1 vs. 2 4.076 2.117* 4.928* 3.845
Group 1 vs. 3 5.269 2.567* 5.598* 4.098
Group 1 vs. 4 6.475 3.206* 5.42* 4.032
Group 2 vs. 3 1.192 2.054 .448 1.159
Group 2 vs. 4 2.399 2.812 .967 1.703
* Significant at 95%
178
One Factor ANOVA X-|: Weeks Y-|: Infarct sizes
Comparison: Mean Diff.: :isher PLSD: Scheffe F-test: Dunnett t:
Group 3 vs. 4 1.206 3.165 .193 .761
Table 10.3
Analysis of the relationship between infarct size and time after coronary artery ligation
(One-Way Analysis of Variance with Multiple Comparisons).
Key: Group 1, Sudden deaths within first week.
Group 2, Total deaths at first stimulation (1 week).
Group 3, Total deaths at second stimulation (2 weeks).
Group 4, Total deaths at third stimulation (3 weeks).
(Analysis of Dunnett test yields similar results to Fisher and Scheffe)
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One Factor ANOVA Xi: Induclbillty Y-|: Infarct sizes
Analysis of Variance Table
Source: DF: Sum Squares: Mean Square: F-test:
Between groups 2 188.059 94.03 7.586
Within groups 54 669.36 12.396 p = .0012
Total 56 857.419
Model II estimate of between component variance = 40.817
One Factor ANOVA X]: Induclbillty Yi: Infarct sizes
Group: Count: Mean: Std. Dev.: Std. Error:
Group 1 12 11.092 5.06 1.461
Group 2 39 7.015 2.878 .461
Group 3 6 5.4 3.822 1.56
One Factor ANOVA Xi: Induclbillty Yi: Infarct sizes
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t:
Group 1 vs. 2 4.076 2.33* 6.15* 3.507
Group 1 vs. 3 5.692 3.53* 5.227* 3.233
Group 2 vs. 3 1.615 3.096 .547 1.046
* Significant at 95%
Table 10.4 (legend on following page)
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Table 10.4: Analysis of the relationship between inducibility and infarct size (One-Way
Analysis of Variance with Multiple Comparisons).
Key: Group 1, Sudden deaths within first week.
Group 2, Inducible dogs assessed at first stimulation (1 week).
Group 3, Non-inducible dogs.




The experiments described in this thesis raise several
interesting points with regard to the aims stated earlier. Firstly,
attention has been drawn to the role of adrenergic factors in the
genesis of ventricular arrhythmias, and in particular how the
respective contributions of a and p stimulation may vary under
conditions of ischaemia and infarction. Secondly, it has been shown
that protection against malignant ventricular arrhythmias and
sudden death may not necessarily be anticipated from a drug's known
electrophysiological properties in vitro. We may have helped clear
some of the controversy surrounding the use of H2 receptor
antagonists in patients with ischaemic heart disease, but we have
shown that an established antiarrhythmic agent may possess
life-threatening proarrhythmic features. Finally, valuable
information is provided with regard to the applicability of
post-infarcted canine models for chronic electrophysiological
studies. These points are considered in turn below.
11.1 Adrenergic Factors in Arrhvthmoaenesis
Despite Govier's description of myocardial a receptors over 20
years ago, studies into the cardiac effects of adrenergic stimulation
continued to concentrate largely on the p adrenergic system,
possibly because the physiological effects of myocardial a
stimulation remained unclear. Interest however was renewed after
the observation that a number of a adrenoceptor antagonists
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exhibited antiarrhythmic effects in experimental models. A further
step was the classification of a adrenoceptors into a-| and <X2
subtypes (Langer, 1977); this enabled further exploitation of the
antiarryhythmic potential of a-| adrenoceptor antagonists without
the attendant risks of increased myocardial noradrenaline
concentrations seen with non-specific a blockade. Results with a
adrenoceptor antagonists, however, have always been open to the
argument that any antiarrhythmic activity may be secondary to
peripheral (including coronary artery) a antagonism. Accordingly,
UK-52046 has been developed as an a-| adrenoceptor antagonist with
selective affinity for myocardial a receptors. Radioligand binding
studies have confirmed marked affinity for post-junctional a-j
adrenoceptors (K = 4.5 x 10"11) and preliminary results have
suggested antiarrhythmic activity without the haemodynamic
consequences of peripheral vasodilatation (Pfizer Central Research,
unpublished communication).
Results of our studies confirm the antiarrhythmic potential of
the drug: thus in the halothane-adrenaline model UK-52046 was
effective at a dose of 3.8 ± 1.4 ug/kg while a comparable protective
dose of atenolol was 14.6 ± 2.1 ug/kg. This is similar to the results
of Maze and Smith (1983) with the a-\ adrenergic antagonist
prazosin, and it is interesting that we, too, demonstrated a
synergistic response with a combination of a and p antagonism
(effective dose of each 0.36 ± 0.1 ug/kg). UK-52046 did not produce
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a significant fall in blood pressure in this experiment, but the
pressor response to adrenaline was attenuated: in view of what has
already been said regarding the factors necessary for the production
of the arrhythmia (chapter 3.2.2 ) it might therefore be argued that
the drug was antiarrhythmic by nature of a peripheral haemodynamic
action. In a modification of the same experiment which does not
depend on a pressor response, however, the parent company has
infused adrenaline into a halothane-respired anaesthetised dog at
such a rate as to produce a continuous ventricular arrhythmia. In
these experiments the addition of increasing intravenous doses of
UK-52046 has resulted in abolition of the arrhythmia without
accompanying falls in blood pressure (Pfizer Central Research,
unpublished communication).
Significant falls in blood pressure were however apparent in
the arrhythmia occurring 24 hours after coronary artery ligation,
where a significant increase in the number of sinus beats resulted
from the administration of 16 mg/kg of drug. Earlier studies with
non-specific a antagonists had shown little effect on this particular
arrhythmia (Maling et al, 1959), but more recent investigations with
prazosin using isolated papillary muscle and Purkinje fibre
preparations have shown a depression in the maximal upstroke
velocity and a dose-dependent prolongation of action potential
duration (Dukes and Vaughan Williams, 1984). It is possible that
UK-52046 may share some of these electrophysiological effects and
possess sufficient class 1 activity to suppress the '24 hour'
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arrhythmia while at the same time being unable to influence the
ouabain-induced arrhythmia. It is of interest that atenolol
exacerbated the ouabain-induced arrhythmia, since reference has
already been made to this phenomenon with certain alternative p
adrenergic antagonists (chapter 3.2.1).
One particularly interesting aspect to the studies described in
chapter 5 was the finding that, while atenolol (100 ug/kg)
significantly reduced the ectopic response to adrenaline after
coronary artery ligation, it was less effective than UK-52046,
where a dose of 3.7 ± 1.4 ug/kg prevented the arrhythmia in 6/6
dogs. Furthermore, the combination of a-^ and (3-| antagonism
appeared no better than a-j blockade alone. While this may be at
variance with the synergy observed in the halothane-adrenaline
model, it may be seen as a confirmation of the enhanced a
responsiveness following ischaemia (Juhasz-Nagy and Aviado, 1976;
Sheridan et al, 1980). In this model too, haemodynamic changes were
apparent at higher doses of UK-52046, but as in the '24 hour' model,
this was a feature only at doses greater than those at which
antiarrhythmic efficacy was apparent. It is presumably the intact
autonomic reflexes in the conscious animal which mediates the
tachycardia in the adrenaline-induced arrhythmia after coronary
artery ligation, since this (the tachycardia) was not a feature in the
halothane adrenaline model.
A dose-dependent hypotensive action was also apparent in the
arrhythmias of acute coronary ischaemia, where we demonstrated a
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significant antiarrhythmic effect of UK-52046 at a dose of 8 ug/kg.
These results are in agreement with similar studies using various a
adrenoceptor antagonists in the dog (Benfey et al, 1984), the
guinea-pig (Penny and Sheridan, 1982), the cat (Sheridan et al, 1980;
Davey, 1981) and the pig (Benfey et al, 1984). Having demonstrated
this effect in one reentrant model, it is interesting to speculate on
why the drug was ineffective against those arrhythmias generated
by programmed electrical stimulation. This may relate to the
severity of the particular model used: we have already seen from
chapters 7 and 8 that mexiletine and racemic tocainide respectively
failed to demonstrate significant protection in the same model
despite apparent efficacy in alternative arrhythmia models. The use
of conscious dogs is a further factor which must be taken into
account, as it allows the study of potential antiarrhythmic action
where the arrhythmogenic conditions of high circulating
catecholamines and enhanced sympathetic tone are not blunted by
general anaesthesia. Our results with an cl-\ adrenoceptor antagonist
and programmed stimulation are similar to those of Wilber et al
(1987) who demonstrated no protection against the arrhythmias of
programmed stimulation in conscious dogs dosed with prazosin. In
the same study, however, prazosin afforded significant protection
against the arrhythmias of acute ischaemia, in this case ischaemia
produced by the introduction of a 150 uA current in the left
circumflex coronary artery (chapter 3.3.3). Since, in the study
mentioned, prazosin (like UK-52046 in our study) did not produce any
187
electrophysiological changes, the authors conclude "the
antifibrillatory efficacy of (prazosin) is not derived from direct
electrophysiologic actions manifest in normal noninjured tissue, but
rather possibly is due to primary or secondary electrophysiologic
actions displayed in acutely ischemic tissue or to a blunting of
those electrophysiologic consequences of acute ischemia that are
mediated by a-j-adrenergic stimulation". In support of the latter
hypothesis, the authors point to the work of Sheridan and Culling
(1985) which showed that the attenuation of the
electrophysiological consequences of ischaemia by a adrenergic
antagonists was mediated by adrenergic rather than direct
myocardial electrophysiological effects in an isolated preparation.
Our results did not demonstrate any significant
electrophysiological changes after UK-52046, but previous studies
in isolated preparations have demonstrated a-mediated changes in
refractory periods (Govier, 1967), positive inotropy (Schumann,
1978) and prolongation of action potential duration (APD) (Benfey,
1982). If, as has been suggested, a adrenergic responsiveness is
enhanced under ischaemic conditions, then a-mediated prolongation
of APD in ischaemic areas may combine with p-mediated shortening
of APD in non-ischaemic areas to produce the arrhythmogenic milieu
suitable for the development of reentrant pathways (Vaughan
Williams, 1985). The cellular events mediating these changes remain
unclear, as contractility appears to be augmented without increases
in cyclic AMP (unlike p stimulation) (Watanabe, 1977); nevertheless,
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it is thought that these a-mediated effects may involve modulation
of intracellular calcium (Sharma et al, 1983). Intracellular calcium
accumulation during myocardial ischaemia is known to contribute to
the disruption of cellular metabolism and to the production of
irreversible injury (Nayler et al, 1979; Jennings and Reimer.1981).
Our studies have demonstrated significant haemodynamic
changes after administration of UK-52046. It is a limitation
therefore of all the models, but the arrhythmias of acute coronary
ischaemia in particular, that we were not able to include in our
experimental protocol the measurement of either coronary artery or
regional myocardial blood flow. Alpha adrenergic receptor
stimulation is thought to play an important role in the regulation of
coronary blood flow (Thomas et al, 1984), but studies have
suggested that the effects of catecholamines on coronary resistance
may be mediated by a 2 receptors (Holtz et al, 1982; Heusch et al,
1984) and that collateral coronary vessels may be devoid of a
receptors in general (Murray et al, 1984). Furthermore, in their study
of a adrenergic contributions to dysrhythmias during myocardial
ischaemia and reperfusion in cats Sheridan and coworkers (1980)
studied regional myocardial blood flow with radiolabeled
microspheres and found that pretreatment with the non-specific a
antagonist phentolamine had no effect on flow during any of the
intervals studied.
Few results are available for studies of a adrenoceptor
antagonists in man: Nickerson and Brown (1951) showed that
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pretreatment with the non-specific a antagonist dibenamine
resulted in an almost complete suppression of the arrhythmias
associated with cyclopropane anaesthesia. Antani and Srinivas
(1973) in a study of 25 patients, infused phentolamine intravenously
at a rate of 0.5 mg/min: of 13 patients with ventricular arrhythmias
of various aetiologies, 10 (77%) responded with complete abolition
of the arrhythmia while the remaining 3 (23%) exhibited partial
suppression. Gould et al (1975) studied the effects of oral
phentolamine, 50 mg four times daily, in a study of 30 patients with
uncomplicated acute myocardial infarction: in a double-blind,
placebo-controlled study they demonstrated a significant (p<0.05)
reduction in the number of ventricular ectopic beats in the patients
receiving phentolamine. Our results suggest that a-j adrenergic
modification may prove to be a protective therapeutic measure in
patients with recurrent ischaemic attacks, a population known to be
at high risk of sudden death.
11.2 Drug Protection Against Ventricular Tachycardia and Death
Our studies with programmed electrical stimulation in a
chronic canine model of myocardial infarction have shown
significant antiarrhythmic protection for R and S tocainide and
atenolol; conversely, the use of racemic tocainide and mexiletine did
not reach statistical significance when compared with placebo.
With regard first to the results of our study with the
enantiomers of tocainide, it has been recognised for some time that
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the separation of the optical isomers of antiarrhythmic compounds
may be associated with differentiation of specific actions (Howe,
1963; Howe and Shanks, 1966). Much of the initial work in this field
has concentrated on the p adrenoceptor antagonists (Whitsitt and
Lucchesi, 1967; Howitt et al, 1968; Barrett and Cullum, 1968), but
more recently studies have been extended to include also the class 3
(Lynch et al, 1984) and class 4 (Bayer et al, 1975; Au et al, 1987)
agents. In the group of dogs which received racemic tocainide, 3
became non-inducible (not significant when compared with placebo).
This is similar to a previous study using programmed stimulation in
post-infarcted dogs, where 4 of 8 animals became non-inducible
after the racemic mixture (Brachmann et al, 1984). A corresponding
clinical study (Easley et al, 1985) demonstrated only 10-20%
efficacy with the drug. There are no reports of specific
antiarrhythmic studies with the enantiomers of tocainide, but
Woosley and coworkers in Nashville are reported to have
demonstrated a three-fold affinity for the sodium channel when the
R enantiomer was compared with the racemic mixture, (personal
communication). Tocainide has been reported to exacerbate certain
arrhythmic states, both in animal (Brachmann et al, 1984) and
clinical (Velebit et al, 1982) studies, but there was no suggestion of
a proarrhythmic response to the racemate or either enantiomer in
our studies with the drugs.
Mention has already been made of the ability of class 1b drugs
to shorten action potential duration (APD) in in vitro studies using
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intracellular micro-electrodes (chapter 2.2.2). However, the same
drugs also slow the kinetics of the sodium channel, so that the
effective refractory period (ERP) of the tissue is not shortened to
the same extent as the APD and the ERP:APD ratio is effectively
increased (table 2.2). In the present study with the drug in vivo, the
QTC interval (as an index of APD) showed no significant change as
the result of racemate or either enantiomer and refractory periods
were similarly unchanged (figure 8.3). Our results are in agreement
with earlier in vivo studies which showed that tocainide does not
alter AV conduction (PR interval) or intraventricular conduction
(QRS duration) (Anderson et al, 1978; Moore et al, 1978; Oshita et al,
1980). In vitro studies, however, have demonstrated enantiomeric
differences in maximal rates of depolarization indicating a specific
receptor interaction and a possible explanation for the differences
in antiarrhythmic activity (Carmeliet et al, 1986; Almgren et al,
1987). Our finding of pharmacological differences between the R(-)
enantiomer and the racemic compound in this class 1 antiarrhythmic
agent must now open up the field of conventional antiarrhythmic
therapy, with attention being focused on active moieties within
parent compounds. It is also possible that some of the side effects
of tocainide, such as those which have restricted the use of the drug
in the UK (Volosin et al, 1985) may be related to enantiomeric
characteristics.
Mexiletine was a further class 1b drug whose effects were
compared with those of atenolol in the study described in chapter 7
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and whose enantiomers were the subject of investigation in chapter
8. Like racemic tocainide, mexiletine was not found to be
significantly different from placebo in protecting against the
arrhythmias of programmed stimulation. While there appears to have
been little work with animal models, the effects of racemic
mexiletine on the inducibility of arrhythmias by programmed
electrical stimulation in man has been variously reported by a
number of authors (Table 11.1).
Investigator No. of Patients Monotherapy (%) Combination (%)
Ruskin et al, 1980 25 9 (36) 13 (52)
Dimarco et al, 1981 35 9 (26) 13 (37)
Breithardt et al, 1981 1 2 4 (33) 9 (75)
Palileo et al, 1982 1 1 1 0) --
Podrid et al, 1983 36 3 (8) 11 (31)
Waspe et al, 1983 33 1 (3) 7 (21)
Saksena & Craelius, 1983 1 9 7 (37) --
Kasanuki et al, 1983 20 8 (40) -
Fenster and Kern, 1983 5 2 (40) --
Schoenfeld et al, 1984 118/148 23/188 (19) 53/148 (36)
Kim et al, 1986 25 -- 4 (16)
Table 11.1
Previous results from the use of mexiletine in electrophysiological
studies with programmed electrical stimulation. Values include
examples of where mexiletine was tested alone (monotherapy) and
in combination with various other antiarrhythmic agents (combination).
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By far the largest study to date has been that of Ruskin and
coworkers (1980); using a study population of 148 patients they
were able to induce ventricular tachyarrhythmias in all 148 in the
absence of antiarrhythmic drugs. After the baseline
electrophysiological evaluations all patients then underwent serial
drug testing with one or more conventional antiarrhythmic agents: of
118 patients tested while taking mexiletine alone, 23 (19%) showed
complete suppression of inducible tachyarrhythmias; in addition,
complete suppression was also observed in a further 30 patients
tested with mexiletine in combination with one or more alternative
antiarrhythmic agents (overall suppression 53/148 or 36%).
Dimarco et al (1981) studied 35 patients with electrically inducible
ventricular arrhythmis, all of which were resistant to conventional
therapy. Mexiletine, either alone or in combination with a previously
ineffective agent, resulted in complete suppression of inducible
arrhythmias in 13 patients; in a further 7 the response to
stimulation was said to be 'favourably modified'. In general, results
of the use of mexiletine alone range from 3% to 40% (Table 11.1).
Such figures, however, should be viewed in the light of disagreement
over standard pacing methods and stimulation protocols; definitions
of sustained and non-sustained ventricular tachycardia vary between
authors as do end-points for drug response (complete suppression of
arrhythmia, conversion of sustained into non-sustained tachycardia
or ability to reproduce arrhythmis only with more aggressive
stimulation). Again like our results with tocainide, we demonstrated
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no change in any electrophysiological parameter when mexiletine or
either enantiomer was compared with placebo. This is in agreement
with previous studies which have shown no effect on action
potential duration (Singh and Vaughan Williams, 1972), conduction
times (Okuma et al., 1976) or refractory periods (Campbell, 1982).
In the present study, 16 mg/kg of mexiletine produced a significant
tachycardic effect. Similar effects have previously been ascribed to
a vagal inhibitory action (Touboul et al., 1978) but this would seem
unlikely without associated delays in conductivity, in particular
atrioventricular times (as reflected in PR intervals). Since the
increase in heart rate was only apparent after 16 mg/kg, a dose
which produced invariable features of agitation and rigidity, it
would seem more likely that this finding was a reflection of drug
toxicity. To the best of our knowledge, our studies with the
enantiomers of mexiletine represent the first such experiments
with these isomers. R and S mexiletine have been the subject of
pharmacokinetic studies (Grech-Belanger et al, 1986), but there has
not been an evaluation of pharmacological effect.
In comparison to our results with mexiletine, the P-j specific
adrenoceptor antagonist atenolol exhibited significant anti¬
arrhythmic activity in our study with programmed stimulation. This
is similar to previous electrophysiological studies in chronic canine
models which have demonstrated significant antiarrhythmic and
antifibrillatory effects propanolol (Echt et al, 1983), timolol (Gang
et al, 1984) and sotalol (Patterson et al, 1984). Experience with
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programmed electrical stimulation in man appears limited and
unclear; Kasanuki et al (1983) found propranolol to be ineffective in
each of 3 patients under study, while Kim et al (1986) found the
same drug effective (alone and in combination) in preventing the
induction of ventricular tachycardia in 10 of 25 patients.
It has been suggested that studies such as these are more
appropriate as evidence of the antifibrillatory effects of p
adrenergic blockade in the heart, but our study clearly shows that
atenolol prevented the recurrence of ventricular tachycardia as well
as protecting against ventricular fibrillation. These antiarrhythmic
studies are similar to those of Rossi et al (1983) who, in a study of
182 patients given intravenous atenolol within 5 hours (mean) of the
onset of chest pain, found a threefold (p<0.001) reduction in the
incidence of ventricular ectopic beats.
Unlike many (3 adrenergic receptors antagonists, atenolol is
devoid of the membrane-stabilising properties which have been
thought responsible for antiarrhythmic effects of beta-blockade in
the past (Somani and Lum, 1965). Nevertheless, we did identify 2
electrophysiological characteristics which did distinguish atenolol
from mexiletine and placebo, and which may account for the drug's
antiarrhythmic action. Prolongation of the effective and functional
refractory periods has been noted previously (Gang et al., 1984) and
is most likely a reflection of antagonism of the high levels of
circulating catecholamines and sympathetic tone pertaining in the
conscious dogs during programmed stimulation: both sympathetic
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nerve stimulation (Kralios et al., 1975) and exogenous catecholamine
administration (Hoffman and Singer, 1967) have been shown to
shorten refractory periods but beta-adrenoceptor antagonism has
been shown to have no effect on refractoriness in anaesthetised
dogs (Hoffman and Singer, 1967). Nevertheless, by delaying
depolarisation of myocardial fibres in possible reentrant pathways,
this antagonism of catecholamines-induced reduction in
refractoriness must be considered protective. The significant fall
in heart rate observed in the study may be similarly antiarrhythmic;
El-Sherif and coworkers (1978), in a study of reentrant ventricular
arrhythmias in the late myocardial infarction period in the dog
demonstrated that the propensity of sympathetic stimulation to
induce arrhythmias was primarily due to its tachycardic effect. A
previous study with propranolol (Hope et al., 1974) had shown a
protective action of propranolol which was antagonised when the
heart rate was returned to control values by atrial pacing.
Furthermore, in a review of some of the larger prospective trials
with the p adrenergic antagonists, Kjershus (1985) drew attention to
the almost linear relationship between the reduction in resting
heart rate and the associated fall in mortality (figure 11.1).
11.3 Proarrhvthmic Effects of Drugs
Results from chapter 9 indicate that neither cimetidine nor
ranitidine are proarrhythmic in a chronic canine model, the
suitability of which was confirmed by the proarrhythmic effects of
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quinidine.
The first description of chronic canine models being used for
proarrhythmic studies appears to have been in 1980 when Lucchesi
and coworkers, in a study of the antiarrhythmic effects of
procainamide, showed that ventricular tachycardias could be
exacerbated by subtherapeutic levels of the drug. These findings led
to a study (Patterson et al, 1981) where non-inducible dogs were
treated with intravenous lignocaine before being rechallenged with
programmed stimulation. Of the 16 animals tested, repeat
stimulation produced non-sustained VT in 4, sustained VT in 9 and
ventricular fibrillation in 1. Similar results have been demonstrated
in canine models with the class 1c drug flecainide (Zimmermann et
al, 1985; DiCarlo et al. 1985). There appears to have been very little
experimental work involving other (non-antiarrhythmic) drugs, but
Dobmeyer et al (1982) demonstrated alterations in refractory
periods associated with proarrhythmic responses in 8 of 9 patients
following the administratiuon of 200 mg of caffeine.
It has already been mentioned how inhomogenous prolongation
of the QT interval may be an inherently proarrhythmic mechanism
(chapter 3.4), and this is a possible explanation for our results with
quinidine, since QTC increased from 0.325 ± 0.01 to 0.355 ± 0.005
(p<0.05 compared with placebo and pretreatment values). It is
interesting that the ERP did not alter as the result of drug, since
this represents an effective decrease in the ERP:APD ratio (table
2.2). The anticholinergic effects of the drug may also be a factor
198
(Goldstein et al, 1973) and drug levels too may be important, since
many antiarrhythmic drugs exhibit a biphasic response curve with
reversal of antiarrhythmic effects at higher doses. This has been
suggested for quinidine (Heissenbuttel and Bigger, 1970), although
proarrhythmic effects have been demonstrated within the usually
accepted 'therapeutic' range (Jenzer and Hagemeijer, 1976).
No explanation for a possible proarrhythmic action of the
h^-receptor antagonists has been proposed, but it has been
suggested that by blocking dopamine receptors, the drugs may
facilitate arrhythmia production by virtue of the associated hyper-
prolactinaemia (Cohen et al, 1979). It is known that cimetidine
therapy is associated with an elevated serum prolactin level
(Carlson and Ippoliti, 1977); furthermore, prolactin is known to be
proarrhythmic in rats (Nassar et al, 1974) and patients with
prolactinomas may exhibit unexplained arrhythmias (Cohen et al,
1979). Since many of the patients to whom H2 antagonists are
administered intravenously are frequently seriously ill, it may be
argued that any association with life-threatening arrhythmias is a
reflaction of the underlying disorder. It is also possible that the
arrhythmias are related to the high histamine levels often seen in
such patients (Cohen et al, 1979; Watson et al, 1982), since recent
reports suggest an association between ventricular arrhythmias and
the use of H-j antagonists (Craft, 1986).
The study showed no change in QTC, PR or QRS as the result of
1 99
treatment with cimetidine or ranitidine. These results are similar
to those of Gould et al (1981) who detected no change in AV
conduction or QRS duration in patients given cimetidine. Since these
parameters are all derived from conduction charateristics, our
results are in agreement with Levi et al (1976) who suggested that
histamine's effects on conduction were mediated by H-| receptors. If
cimetidine and ranitidine were to shorten refractory periods, a
proarrhythmic effect could be explained on the basis of early
depolarization of adjacent myocardial fibres in a reentrant pathway.
While we did demonstrate some shortening of both the ERP and FRP,
with cimetidine these changes did not reach significance and with
ranitidine numbers were too small to permit statistical analysis.
All the drugs under study produced significant increases in
heart rate when compared with placebo. Anticholinergic effects are
most likely the cause of this phenomenon with quinidine, but it is
less apparent why a tachycardia should be observed with cimetidine
or ranitidine. Bradycardia, however, has not been a universal finding
with these drugs. Engel and Luck (1979), in a study of 10 patients
before and after an infusion of 300 mg of cimetidine, were unable to
demonstrate any significant effect on sinus node function, and
toxicological studies in dogs have reported tachycardia in
association with high-dose cimetidine therapy (Leslie and Walker,
1977). In view of the doses at which tachycardia became apparent in
this study (cumulative doses of 32 mg/kg and 16 mg/kg for
cimetidine and ranitidine respectively) it seems most likely that
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this has been a feature of drug toxicity in both cases.
When considering the H2 antagonists in the field of cardiac
disease in general, it is interesting to speculate on a recent article
(Toda, 1987) which demonstrated that histamine-induced coronary
artery spasm was mediated by Hi receptors in smooth muscle, and
that coronary artery dilatation was a feature of H2 stimulation. One
conclusion of this might be that the use of H2 receptor antagonists
could produce unopposed Hi-mediated coronary artery spasm and, if
what we have said regarding the patho- physiological aetiology of
sudden cardiac death is true, this might be a contributory factor,
especially in the post-infarction population. A personal
communication from the Boston Collaborative Drug Surveillance
Program in Massachusetts, however indicated that this problem had
not as yet been addressed in man.
11.4 The Significance of Infarct Sizes
Our results from chapter 10 confirm a reduction in the
inducibility of arrhythmias as a function of time following
experimental myocardial infarction. This would appear to be the only
such study, for although anecdotal stories exist of dogs exhibiting
arrhythmias on stimulation for up to 2 years and more, we have been
unable to find any evidence of this in the literature, nor would such
stories be in keeping with our results.
One argument which may be levelled against our findings is that
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the most inducible animals will die earlier as the result of
programmed stimulation; thus any evaluation of inducibility against
time will have an inherent bias. To overcome this particular problem
would require a study where only surviving animals were included
for statistical analysis. Another possibility, however, is that the
reduction in inducibility reflects a reduction in infarct size. It is
known clinically that scar formation usually becomes apparent
during the third week after myocardial infarction. Increased
fibroblastic activity associated with removal of necrotic tissue and
the appearance of widening bundles of collagen ultimately results in
a thin scar, formed principally from pre-existng stroma and new
connective tissue (Hurst et al, 1982). Our results show a tendency
towards a time-dependent reduction in infarct size, although some
inter-group variations in the later weeks did not reach statistical
significance. Using a similar chronic canine model, Wilber and
coworkers investigated this phenomenon in a study of 30 dogs
subjected to programmed electrical stimulation 5 days after
coronary artery ligation. Results indicated that infarct size was
much larger in inducible (24.7 ± 1.7% of LV mass) than in
non-inducible (5.3 ± 1.1%) (p<0.001) animals (Wilber et al, 1985).
One particularly interesting aspect to this study was the
observation that a number of previously well animals died suddenly
and unexpectedly during the first postoperative week. That fact that
2 of these dogs died when exercised outside in cold weather
suggests that coronary vasospasm may have been involved:
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ventricular electrical instability is known to be at a maximum until
the sixth post-operative day in the dog (Thompson and Lown, 1972)
and a similar model of distant ischaemia has been successfully
employed for sudden death studies (chapter 3.3.3). Taken as a group,
these animals had a significantly greater mean infarct size than
surviving dogs, either inducible or non-inducible. In the same
analysis, the difference between inducible and non-inducible
animals did not reach statistical significance (table 10.4). However,
these results are heavily influenced by the nature of weekly
stimulations for the dogs under study: to study more closely the
phenomenon of infarct size as a function of inducibility would
require sacrificing every animal when first stimulated.
In general, the infarct sizes obtained in our studies are smaller
than those published by other investigators using mongrel dogs. This
may well relate to the nature of the animal under study; collateral
circulations are known to vary greatly amongst different species of
dog and may have an important role in determining the outcome of
coronary ligation (Chardack et al, 1964). Sudden occlusion of the left
anterior descending artery in beagles has been shown to produce
little ischaemia (as assessed by early arrhythmic activity) (Shanks
and Dunlop, 1967), while in greyhounds a critical stenosis alone
produces sufficient ischaemia to be included as an arrhythmia model
(chapter 6). Many of the animals which died from acute ischaemic
ventricular fibrillation during surgery were those in which attempts
had been made to produce larger infarcts; however, since results of
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staining with TTC were rarely successful when attempted less than
2 hours from the initial ligation, this is difficult to assess
scientifically.
Macroscopic enzyme-mapping verification of infarct size using
TTC appears to be an accurate method of determining the extent of
experimental myocardial necrosis (Lie et al, 1975; Fishbien et al,
1981). Although it has been suggested that the method may not
accurately predict recovery of myocardial fibres after reperfusion
(Barnard et al, 1986), it nevertheless remains the investigation of
choice in both occlusion/reperfusion (Simpson et al, 1987) and
occlusion-only (DeBoer et al, 1982) studies. In our studies, infarct
mass was determined gravimetrically; computer-assisted
planometric determination of infarct mass has also been described,
but there does not appear to be any distinct advantage between the
two methods (Lynch et al, unpublished results).
11.5 Criticisms. Suggestions and Future Directions
I include this section primarily to concentrate on certain
specific aspects of our work which may be considered controversial,
or for which (during the course of manuscript review) we have been
criticised. Automaticity models of cardiac arrhythmias have always
been open to questions regarding their applicability to the clinical
situation and I do not intend to add further to this particular debate;
instead I would wish to limit this section specifically to some of
the arguments relating to programmed electrical stimulation in the
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chronic canine model.
One particular criticism of our model relates to the finding
that the use of 3 closely-coupled extrastimuli may result in
arrhythmias in normal dogs (Hamer et al, 1984). While we accept
these results, we would point out that in the particular study
referenced, the end-point for arrhythmia induction was ventricular
fibrillation, and the technique employed stimulating current
strengths of up to fifteen times diastolic threshold. It is well known
that currents of sufficient strength will produce fibrillation (such
is the basis for the ventricular fibrillation threshold) and that
threshold currents are reduced with increasing numbers of
extrastimuli (Moore et al, 1986), but this is the reason why we have
consistently stimulated at twice diastolic threshold. We would also
note the results of several previous studies which have failed to
produce arrhythmias using similar pacing methods in sham-operated
dogs (Michelson et al, 1981; Garan et al, 1981; Patterson et al,
1982(b); Lown et al, 1986). When ventricular fibrillation did occur
during stimulation, it was frequently preceeded by a variable period
of sustained monomorphic ventricular tachycardia (figures 11.2,
11.3) and in this respect parallels the findings for sudden cardiac
death in man (chapter 1.3.2).
Animals which fibrillated during the course of our studies were
not resuscitated for two reasons: initial experience with standard
defibrillation equipment had been singularly ineffective in reversing
fibrillation, and even with modified plates strapped to the animals'
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chests we were able successfully to defibrillate only a minority of
dogs. Another reason for not pursuing the problem was to avoid the
confounding influence of repeated and occasionally prolonged
resuscitative efforts on the outcome of subsequent investigations
(Ehsani et al, 1976). Since the survival of the animals was a major
consideration in all of the studies with programmed stimulation,
this was one reason for not pursuing a reproducible non-sustained
VT with more aggressive pacing methods in an attempt to achieve a
sustained arrhythmia. Our experience has been that increasing the
nunber of extrastimuli and reducing coupling intervals may result in
a higher incidence of sustained VT, but at the expense of greater
pretreatment mortality. In this respect our results are similar to
the experiences of Lucchesi and co-workers (Lynch et al, 1987).
Futhermore, results from the same laboratory have shown a highly
predictive relationship between the vulnerability to initiation of
either sustained or non-sustained VT (by programmed stimulation)
to the development of sudden death in response to a subsequent
ischaemic insult at a distant site (chapter 3.3.3)(Wilber et al,
1985), thus confirming non-sustained VT as an adequate substrate
from which to base an antiarrhythmic study. It has been argued that
unimorphic VT is more specific for ischaemic damage than
polymorphic arrhythmias. While this may be proven for clinical
electrophysiological testing, the question does not appear to have
been addressed in animal studies. For this reason we accepted both,
providing the non-sustained arrhythmias were reproducible in any
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given animal.
Resuscitation of animals might have been a more
straightforward procedure had we chosen to use anaesthetised,
open-chested animals for programmed stimulation. While such a
method would also have made more simple the management of
arterial access and the occasionally agitated animal, it would have
restricted the number of times we could have stimulated any
particular dog. Furthermore, we believe the relevance of a conscious
model is of crucial importance in the evaluation of antiarrhythmic
agents, especially when dealing with drugs with inherent
sympatholytic activity such as the a or p-adrenergic antagonists.
The role of an intact autonomic nervous system in the genesis of
cardiac arrhythmias has been recognized for some time (Lown and
Verrier, 1976; Corr and Gillis, 1978), and in a similar chronic canine
model, Schwartz and Stone (1980) have demonstrated that
sympathetic stimulation can facilitate the induction of ventricular
fibrillation; furthermore, neurogenic activity can modify the effects
of antiarrhythmic drugs (Bigger et al., 1982).
Our definition of non-sustained VT was reached arbitrarily.
Since this field of experimental pharmacology is relatively new,
there has been little time for agreement on standard definitions for
arrhythmias; thus the recent Lambeth conventions are particularly
welcome in their recognition and tackling of such problems, even if
decisions may not have met with unanimous approval (Walker et al,
1987). Based on the studies of Gibson and Lucchesi (1980),
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[non-sustained VT as 3 or more ventricular ectopic beats]; Michelson
et al (1980(b)), [3 or more]; Lynch et al (1984), [5 or more]; Cobbe et
al (1985), [4 or more] and Moore et al (1986), [4 or more], we chose 4
ventricular ectopic beats as the minimum requirement for
establishing a non-sustained VT. In retrospect we are able to stand
over this figure, since once an animal exhibited 4 extra beats, we
could be fairly sure that, on rechallenge, this would be at least
consistent, if not associated with a more dramatic ectopic response.
Conversely, non-inducible dogs commonly produced 2 or 3 extra
beats during pre-drug stimulation, but only one of the 24 animals
studied developed 4 extrasystoles, and this only once during the
protocol.
In retrospect, our definition of sustained VT was probably too
demanding. Again, we were faced with conflicting figures from other
researchers and the production of prolonged periods of VT in some
early studies led us to adopt the criteria of a self-perpetuating
arrhythmia of 5 min duration as our standard. While there can be no
argument as to the authenticity of this as a sustained arrhythmia, in
retrospect it was too severe a model, and led to the loss of a number
of dogs which fibrillated after a variable period of arrhythmia. This
probably relates to haemodynamic compromise, and is the reason for
termination of the arrhythmia by burst pacing by a number of other
researchers (Michelson et al, 1980(a); Garan et al 1980; Lynch et al,
1984; Cobbe et al, 1985). Thus it might be prudent in future studies
to refine our definition of sustained VT to 'a self-perpetuating
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arrhythmia of 30 sec duration or which required overdrive pacing for
termination'. In this way we would avoid the high mortality from
pretreatment stimulation (chapter 10).
Reference has already been made to the theoretical advantage
of using an occlusion/reperfusion model in studies with programmed
electrical stimulation (chapter 3.3.2). Not having compared the two
methods in a scientific study, we are not in any position to comment
on this particular debate, but we can dispel the argument that
reperfusion is an essential prerequisite for arrhythmia generation
(Karagueuzian et al, 1979). Whether this may be a feature of our
particular model (the greyhound) we cannot say, but it is clear that
by occluding alone we avoid the high incidence of reperfusion
ventricular fibrillation (Battle et al, 1974).
Our electrophysiological studies included the measurements of
electrocardiographic parameters and refractory periods. Possible
modifications here might include the separate determination of
infarct and normal zone refractoriness, possibly by constructing
strength/interval curves along the lines first suggested by
Michelson et al (1980(a)). This would obviously involve adaptation of
the unipolar electrodes presently used, with conversion also of
threshold voltages to amperage values, but would allow the study of
drug effects in both infarcted and normal myocardium. Ventricular
activation times and VT cycle lengths are essentially measures of
conductivity and can be determined from normal and infarcted
electrograms and the surface electrocardiogram respectively (Lynch
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et al, 1987). Using the equipment presently employed, there is no
reason why these parameters should not be added to those variables
currently measured. One final point relates to the measurement of
the QT interval. Reference has already been made to Bazett's
discovery of an inverse relationship between the QT interval and
heart rate, but although the equation is well known (and widely
used), there are those who remain unconvinced of the accuracy of the
calculation (Somberg et al, 1985). For this reason, many
electrophysiologists now refer to the paced QT, a QT interval as
determined during fixed atrial pacing. The inability of our particular
model to deal with variations in coronary artery or regional
myocardial blood flow has been considered in detail already
(chapter 11.1).
And future directions? As regards surgical proceedures or
stimulation protocols, the inclusion of additional atrial and normal
zone/ischaemic zone electrodes could provide further
electrophysiological information, while chronically implanted
arterial and venous lines (for example external jugular and carotid
catheters exteriorized at the nape of the neck) might allow easier
access for blood pressure recording and administration of drugs.
Much has been done in relating induction of arrhythmias with
programmed stimulation to the site of stimulation, stimulus
duration, intensity and polarity, the basic stimulation rate and the
number of extrastimuli (Moore et al, 1986). There appears to have
been little research, however, into the effects of variations in those
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basic biochemical parameters which may be of crucial importance
under ischaemic conditions (chapter 1.1.5). Thus a final refinement
of our experimental set-up might be to monitor arterial oxygen
tension, pH, and electrolyte status, and in so doing note any
associated alterations in inducibility of arrhythmias.
The field of antiarrhythmic drug therapy remains one of the
most fascinating and challenging facets of medicine today, and I
believe our studies open up a number of possible research projects
for the future. Much has still to be learned about adrenergic
mechanisms in normal and infarcted myocardium, while the
protection afforded by the (^-adrenergic antagonists in programmed
stimulation could be followed by studies which concentrate on
slowing of heart rate (for example with the specific bradycardic
agents) or refractoriness (for example with the class 3 agents). Our
results with the enantiomers of tocainide should hopefully
stimulate interest into isolating and testing the isomers of other
antiarrhythmic agents. Proarrhythmic studies are in their infancy,
and must become a routine investigation in the 'work-up' of new
antiarrhythmic agents as well as a host of drugs with direct or
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Figure 1.
Relationship between fall in heart rate and reduction in mortality
using some of the commoner beta-adrenergic receptor antagonists:







Example of ventricular fibrillation following several seconds of
monomorphic ventricular tachycardia in response to programmed
electrical stimulation prior to administration of drug.
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Example of ventricular fibrillation following several seconds of
monomorphic ventricular tachycardia in response to programmed
electrical stimulation after 16 mg/kg of quinidine.
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